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ABSTRACT 
Prep1 is an homeodomain transcription factor belonging to the TALE 
proteins, including also Pbx1, which plays an essential role in hematopoiesis, 
organogenesis and development. Prep1 forms transcriptionally active 
complexes with Pbx1 and regulates the activity of several genes. The Prep1 
null mutation leads to embryonic death at a very early stage. Therefore, Prep1 
hypomorphic (Prep1i/i) mice have been generated. Prep1 heterozygous 
(Prep1i/+) mice, which express only 55-57% of protein, have a complex 
metabolic phenotype with at least two relevant features. One is the presence of 
smaller but otherwise normally structured islets with reduced fasting and post-
loading plasma insulin levels. The second is increased insulin sensitivity in 
skeletal muscle and in liver which is accompanied by protection from 
streptozotocin-induced diabetes. In muscle, decreased Prep1 levels are 
followed by an increase of the PGC1alpha/Glut4-mediated glucose uptake. In 
liver,  better insulin sensitivity is due to a reduced SHP1 tyrosine phosphatase 
expression followed by an increase of insulin signaling. Also, triglyceride 
levels are significantly reduced in the liver of Prep1i/+ mice. However, the 
molecular mechanism by which Prep1 controls lipogenesis is unclear. In this 
study, we have focused our attention on the role of Prep1 on the regulation of 
the triglyceride synthesis. 
To study the lipogenesis in the liver of the Prep1 heterozygous mice, we have 
examined the expression of the lipogenetic enzyme FAS (Fatty Acid Synthase) 
by real-time RT-PCR analysis. Hepatic expression of FAS is significantly 
decreased. Western Blot analysis have shown increased phosphorylation of 
PKCzeta, LKB1, AMPK and ACC, which may control FAS expression and 
triglycerides production in Prep1i/+ mice liver. Protein and mRNA levels of the 
lipid phosphatase SHIP2, an inhibitor of PI3Kinase/PKCzeta signaling, are 
reduced by 40% in the liver of Prep1i/+ mice. Consistent with these data, 
HepG2 (Human Hepatocarcinoma cell line) cells overexpressing Prep1 display 
increased triglyceride levels and FAS expression, while PKCzeta, LKB1, 
AMPK and ACC phosphorylation is strongly reduced. Moreover, SHIP2 levels 
are increased by 50%. Interestingly, overexpression of Pbx1 cDNA in HepG2 
cells mimicked Prep1-induced triglyceride synthesis. At the opposite, Prep1HR1 
mutant, which is unable to bind Pbx1,  fails to elicit these effects. ChIP and Re-
ChIP experiments indicate that Prep1/Pbx1 complex can bind SHIP2 promoter 
region and regulate its expression.  
These data suggest that Prep1/Pbx1 dimer regulates hepatic triglycerides 
production by increasing SHIP2 levels and thereby inhibiting the 
PKCzeta/AMPK signaling. 
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1. BACKGROUND 
 
1.1 Diabetes 
 
Diabetes mellitus (DM) includes a group of metabolic disorders that 
requires long-term medical attention both to limit the development of its 
devastating complications and to manage them when they do occur. Diabetes 
mellitus is a chronic metabolic syndrome caused by insulin deficiency and 
characterized by elevated glucose levels. The metabolic dysregulation and the 
chronic hyperglycemia associated with DM causes secondary 
pathophysiological damage in multiple organ system, such as eyes, kidneys, 
nerves, heart and blood vessels. 
According to the classification recommended by the American Diabetes 
Association (2004), there are three main form of diabetes: type 1 diabetes 
(T1D), type 2 diabetes (T2D), and gestational diabetes mellitus. 
Type 1 diabetes is characterized by beta cell destruction caused by an 
autoimmune process, usually leading to absolute insulin deficiency. Insulin 
injection is always necessary for survival because T1D patients lack 
endogenous insulin. 
Type 2 diabetes is the most common form of diabetes mellitus and is 
characterized by insulin resistance in peripheral tissue, insulin secretory defect 
of the beta cell and excessive hepatic glucose production (Harrison 2009). 
People with T2D are not dependent on exogenous insulin, but may require the 
hormone  for the control of glucose homeostasis if this is not achieved with diet 
alone or with oral hypoglycaemic agents. The etiology of type 2 diabetes 
mellitus is multifactorial and genetically based, but it also has strong 
behavioral components. 
 
 
1.2 Insulin-Resistance 
 
Insulin is the primary hormone involved in glucose homeostasis and in 
the stimulation of glucose transport. Secreted by pancreatic beta cells in 
response to increase of plasmatic glucose and amino acids levels after feeding, 
insulin promotes the synthesis and storage of carbohydrates, lipid, proteins and 
inhibits their degradation and release into the circulation. 
Insulin-resistance is a common pathological state in which target tissue fail to 
respond properly to normal levels of circulating insulin. Pancreatic β-cells first 
compensate for peripheral insulin-resistance by increasing insulin secretion to 
maintain euglycaemia. Thereafter, impaired glucose tolerance can develop, 
leading to overt clinical type 2 diabetes. The coexistence of insulin-resistance 
and hyperinsulinaemia appears to contribute directly or indirectly to many 
other disorders, such as dyslipidaemia, hypertension, atherosclerosis and a pro-
coagulant state (Samaras et al. 2006).  
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Insulin-resistance is determined by impaired sensitivity to insulin of its main 
target organs, i.e. adipose tissue, liver, and muscle. Insulin regulates glucose 
uptake and circulating free fatty acid (FFA) concentrations. In adipose tissue, 
insulin decreases lipolysis thereby reducing FFA efflux from adipocytes; in 
liver, insulin inhibits gluconeogenesis by reducing key enzyme activities, and 
in skeletal muscle insulin predominantly induces glucose uptake by stimulating 
the translocation of the GLUT4 glucose transporter to the plasma membrane. 
Insulin-resistance leads to increased circulating FFA concentrations and 
ectopic fat accumulation that impede insulin mediated glucose uptake in 
skeletal muscle and elevated glucose production in liver (Zeyda end Stulnig 
2009) (Figure 1).  
 
 
 
Figure 1: Model of the critical role of impaired insulin release in linking obesity with 
insulin-resistance and type 2 diabetes. 
Impaired insulin secretion results in decreased insulin levels and decreased signaling, leading 
to increased food intake and weight gain, decreased inhibition of hepatic glucose production, 
reduced efficiency of glucose uptake in muscle, and increased lipolysis in the adipocyte, 
resulting in increased plasma NEFA levels. The increase in body weight and NEFAs contribute 
to insulin-resistance, and the increased NEFAs also suppress the -cell's adaptive response to 
insulin-resistance. The increased glucose levels together with the elevated NEFA levels can 
synergize to further adversely affect -cell health and insulin action, often referred to as 
'glucolipotoxicity'.  
Adapted from Kahn SE, Hull RL, Utzschneider KM. Nature. 2006;444(7121):840-846 
 
In the liver, insulin is involved in a number of actions responsible for glucose 
control and lipid metabolism. In case of insulin-resistance, insulin levels are 
raised to overcome this resistance. The resulting effects depend on the 
metabolic pathway: a deficient insulin response for glucose metabolism leads 
to increased glucose production in the fasting state, while elevated insulin leads 
to activation of the lipid biosynthetic pathway, resulting in increased VLDL 
production and dyslipidemia. Given the central role played by the liver in 
glucose and lipid metabolism, any imbalance between the entry and the export 
of lipid derivatives results in steatosis. Steatosis and insulin-resistance have a 
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number of reciprocal relationships and can enhance each other. A number of 
arguments suggest that insulin-resistance leads to steatosis and that steatosis, or 
rather the presence of fatty acid (FA) derivates used for triglyceride (TG) 
synthesis, enhances insulin-resistance. In human, steatosis and insulin-
resistance are clearly associated, and lead to an increased prevalence of 
diabetes and cardiovascular risk. A number of mechanisms might explain this 
association, some of which are extrahepatic, such as adipose tissue or diet, 
while some are intrahepatic. 
 
1.3 Insulin signaling in the liver 
 
Hepatocytes are one of three main types of insulin target cells (along 
with myocytes and adipocytes) that carry a large number of insulin receptors 
on their cell surfaces. Insulin signaling can only take place through insulin 
receptors (Chapeau 2005; Taniguchi et al. 2006). 
 
 
1.3.1 Insulin signaling pathway 
 
Insulin binding to its receptor induces complex signaling cascades. The 
insulin receptor is an heterotetrameric bifunctional transmembrane 
glycoprotein comprising two extracellular α subunits and two transmembrane 
β subunits linked by disulfide bonds. The β subunits possess tyrosine-kinase 
activity in their intracytoplasmic domain, which is activated after linkage with 
insulin and phosphorylated on specific tyrosine residues on the receptor itself. 
This phosphotyrosine signal is recognized by protein substrates of the receptor 
that become activated and transmit the insulin signal in the cell. Several 
intracellular substrates of the insulin receptor kinases have been identified. 
Four of these belong to the family of insulin-receptor substrate (IRS1-4) 
proteins (White 1998).  In addition, phosphotyrosines of the insulin receptor β 
subunit can also be recognized by substrates from the SHC and CAP/cbl 
families. Two main pathways diverge from the receptor: one leads to activation 
of phosphatidylinositol 3-kinase (PI3-K), then PKB/Akt or atypical PKC, like 
PKC-ζ and λ and stimulates the metabolic activities such as increased 
glycogen synthesis, lipogensis and inhibition of gluconeogenesis; the other, 
called MAP kinase pathway, leads to activation of cell proliferation and 
differentiation (Figure 2). However, in most cases, a specific effect of insulin 
requires the participation of both the pathways in a complex interplay which 
could explain the pleiotropy and the specificity of the insulin signal (Cusi et al. 
2000). 
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Figure 2: Insulin signaling. 
Insulin binding to the extracellular domain of the insulin receptor elicits a conformational 
change, which in turn leads to receptor autophosphorylation (P) and tyrosine phosphorylation 
of intracellular protein substrates. Two main branching pathways are activated by insulin: (a) 
One is the MAPK signaling cascade, in which the Grb2/Sos pathway leads to activation of Ras 
signaling, affecting cell proliferation and apoptosis. In view of their mitogenic nature, these 
can be characterized as "growth signal" effects. (b) The other is the IRS pathway, which leads 
to activation of kinases dependent upon the heterodimeric (p85/p110) PI3K, such as Akt, also 
referred to as protein kinase B (PKB); Akt modulates enzyme activities that, besides affecting 
NO generation and apoptosis, control glucose, lipid, and protein metabolism. This PI3K-
branching pathway is termed the "metabolic signal." PI(4, 5)P2, phosphoinositide 4,5 di-
phosphate; PI(3, 4, 5)P3, phosphoinositide 3,4,5 tri-phosphate; PDK1 phosphoinositide–
dependent kinase–1; MEK, MAPK kinase. 
 
 
1.3.2 Insulin controls hepatic glucose and lipid metabolism 
 
Insulin controls glucose metabolism in the liver suppressing hepatic 
glucose output by stimulating glycogen synthesis and inhibiting glycogenolysis 
and gluconeogenesis. 
The regulation of gluconeogenesis in the liver is dependent on a number of key 
enzymes: pyruvate carboxylase, phosphoenolpyruvate carboxykinase 
(PEPCK), fructose-1,6-bisphosphatase, and glucose-6-phosphatase (Pilkis and 
Claus 1991). Insulin directly regulates the expression of these genes (Pilkis and 
Granner 1992), inhibiting the transcription of the gene encoding PEPCK or 
fructose-1,6-bisphosphatase and glucose-6-phosphatase and increasing 
transcription of glycolytic enzymes such as glucokinase and pyruvate kinase. 
12 
 
Insulin stimulates glycogen accumulation through a coordinated increase in 
glucose transport and glycogen synthesis. The GSK3, a serine/threonine kinase, 
phosphorylates glycogen synthase and inactivates it. As glycogen synthase is a 
rate-limiting enzyme in glycogen synthesis, inactivation of GSK3 by insulin 
removes the inhibitory effect of GSK3 on glycogen synthase and leads to 
increased glycogen synthesis (Avruch 1998; Virkamaki et al. 1999; Fang et al. 
2000). When glycogen stores and energy requirements are fulfilled, glucose is 
diverted towards lipid synthesis, first by glycolysis, then by the initiation of the 
mitochondrial tricarboxylic cycle and, finally, by lipogenesis in the cytosol to 
produce fatty acids. This means that lipid metabolism is strongly related to 
glucose metabolism in hepatocyte and biosynthetic pathways leading to 
glycogen and TG synthesis activated by insulin (Figure 3). 
 
 
Figure 3: The regulation of glucose metabolism in the liver. 
In the hepatocyte, insulin stimulates the utilization and storage of glucose as lipid and 
glycogen, while repressing glucose synthesis and release. This is accomplished through a 
coordinated regulation of enzyme synthesis and activity. Insulin stimulates the expression of 
genes encoding glycolytic and fatty-acid synthetic enzymes (in blue), while inhibiting the 
expression of those encoding gluconeogenic enzymes (in red). These effects are mediated by a 
series of transcription factors and co-factors, including sterol regulatory element-binding 
protein (SREBP)-1, hepatic nuclear factor (HNF)-4, the forkhead protein family (Fox) and 
PPARγ co-activator 1 (PGC1). The hormone also regulates the activities of some enzymes, 
such as glycogen synthase and citrate lyase (in green), through changes in phosphorylation 
state. GK, glucokinase; Glucose-6-P, glucose-6-phosphate; G-6-Pase, glucose-6-phosphatase; 
F-1,6-Pase, fructose-1,6-bisphosphatase; PEPCK, phosphoenolpyruvate carboxykinase; PFK, 
phosphofructokinase; PK, pyruvate kinase; ACC, acetyl-CoA carboxylase; FAS, fatty-acid 
synthase. 
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1.4 Hepatic lipogenesis 
 
Storage of energy when food is available is determinant for survival. 
Quantitatively, the main form of energy storage is represented by lipids in 
adipose tissue. The origin of the stored lipids can be either the diet or de novo 
synthesis from carbohydrate through lipogenesis. 
Triacylglycerol (TAG) is synthesized by esterification of glycerol-3-phosphate 
with fatty acid (FA). The two major tissues that synthesize FA and TAG at 
high level are the liver and adipose tissue and are also called lipogenic tissues. 
TAG synthesized in the liver is used for VLDL assembly to be secreted to the 
circulation, while TAG synthesized in adipose tissue is stored as the main 
energy storage form in mammals, and is hydrolyzed to release FA into 
circulation to be used by other tissues during periods of energy demand. 
Dysregulation of FA and TAG metabolism often contributes to metabolic 
diseases (Wong and Sul 2010). 
Triglycerides are formed in response to fluxes of non-esterified fatty acids and 
glucose. Glucose provides de novo lipogenesis, via pyruvate citrate which 
generates acetyl-CoA for fatty acid synthesis. 
Increased lipogenesis results from transcriptional activation of many genes 
econding glycolytic and lipogenic enzymes including glucokinase (GK), liver-
pyruvate kinase (L-PK), acetyl CoA carboxylase (ACC), fatty acid synthase 
(FAS), stearoyl CoA desaturase (SCD1) which catalizes fatty acid elongation 
and desaturation steps, and finally mitochondrial glycerol3-phosphate 
acyltransferase (GPAT) and diacylglycerol acyltransferase (DGAT) for TG 
synthesis (Figure 4). 
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Figure 4: Interconnection of metabolic pathways involved in lipid synthesis in the 
endoplasmic reticulum and lipid oxidation in mitochondria of liver and skeletal muscle. 
Among the lipid metabolic enzymes, acetyl-CoA carboxylase (ACC), fatty-acid synthase 
(FAS) and carnitine palmitoyl transferase (CPT) are the three main enzymes that regulate the 
synthesis of malonyl-CoA, which is the principal inhibitor of fatty-acid entry into mitochondria 
for β-oxidation. Stearoyl-CoA desaturase-1 (SCD1) regulates lipid oxidation by converting 
stearic acid (18:0) to oleic acid (18:1). The saturated fatty acyl-CoAs are known to 
allosterically inhibit ACC1, whereas monounsaturated fatty acyl-CoAs are the preferred 
substrates for the lipid synthesis of triacylglycerol (TAG) in the endoplasmic reticulum (ER). 
Malonyl-CoA and stearic acid reciprocally regulate the entry of acyl-CoA into mitochondria by 
modulating the activity of CPTA. Lysophosphatidic acid (LPA) and phosphatidic acid (PA) are 
synthesized in the ER; they are also produced in mitochondria and transported to the ER where 
the terminal enzymes for TAG synthesis are located. Mitochondrial FAS (FAS II) and acyl-
carrier protein (ACP) are involved in fatty-acid synthesis, but their role in lipid metabolism 
remains elusive. ACS, acyl-CoA synthase; AGPAT, acylglycerol-3-phosphate acyltransferase; 
CLS, cardiolipin (CL) synthase; DGAT, diacylglycerol (DAG) acyltransferase; GPAT, 
glycerol-3-phosphate (G-3-P) acyltransferase; MCD, malonyl-CoA decarboxylase; MGAT, 
monoacylglycerol (MAG) acyltransferase; PAP, phosphatidic-acid phosphohydrolase; PGPS, 
phosphatidylglycerophosphate (PGP) synthase; TAG, triacylglycerol; TCA, tricarboxylic-acid 
cycle. 
 
Fatty acid synthesis is a cytoplasmatic process. All acetyl-CoA must be 
exported from the mitochondrial matrix via citrate (first step in Krebs cycle). In 
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the cytoplasm, citrate is split into acetyl-CoA and oxaloacetate. Then, acetyl-
CoA is activated by ACC to malonyl-CoA, the immediate precursor for fatty 
acid synthesis. In mammals, two ACC isoforms exist, each with distinct tissue 
distribution and physiological roles: ACC1 is cytosolic and participates in de 
novo lipogenesis, while ACC2 is mitochondrial and is thought to be involved 
in the negative regulation of mitochondrial β-oxidation by modulating local 
malonyl-CoA levels (Postic and Girard 2008). 
FAS is a single multifunctional polypeptide containing seven catalytic sites and 
is the key enzyme of fatty acid biosynthesis; it elongates a carbon chain 
starting from an acetyl-CoA primer with molecules of malonyl-CoA provided 
by ACC and requires the presence of NADPH and synthesizes Palmitic Acid 
(Foufelle et al. 1996). Palmitate is then released from the enzyme and can then 
undergo separate elongation and/or unsaturation to yield other fatty acid 
molecules.  
To efficiently incorporate newly synthesized fatty acid into triglyceride, a 
fraction of synthesized fatty acids must undergo desaturation to 
monounsaturated fatty acids because the middle position of the glycerol 
backbone is optimally esterified with an unsaturated fatty acid. The enzyme 
stearoyl-CoA desaturase-1 (SCD-1) effects this desaturation and is essential to 
the efficient formation of triglyceride in the absence of adequate dietary 
unsaturated fatty acids. SCD1 catalyzes the synthesis of monounsaturated fatty 
acids, particulary oleate and palmitoleate, which are the major components of 
memebrane phospholipids, TGs, and cholesterol esters. 
Accumulation of lipids has been linked to functional disturbances in various 
tissues and organs, often referred to as lipotoxicity (Unger 1995). Fatty liver is 
associated with hepatic insulin-resistance and β-cell lipotoxicity with impaired 
insulin secretion, both of which trigger diabetes. Thus, the mechanisms that 
regulate the uptake, de novo biosynthesis, and oxidative catabolism of lipids 
are very important.  
 
1.4.1 Regulation of hepatic lipogenesis 
 
All living organisms possess mechanisms for repeatedly reassessing the 
status of long-term energy stores and, when the need arises, making 
compensatory adjustments to adapt their metabolism to the nutritional 
environment. Mammals have developed a complex series of nutrient cues, 
relieved by hormones or impulses from the central nervous system, to regulate 
whole-body metabolism in response to acute deficiencies or to prolonged 
excess or shortage of nutrient supply. Hepatic metabolism plays a key role in 
the regulation of whole-body energy status since the liver is the major site for 
storage and release of carbohydrates and for fatty acid synthesis. Indeed, 
during the postprandial period, net glucose uptake permits the repletion of 
hepatic glycogen stores, the excess dietary carbohydrates being then converted 
into triglycerides to promote long-term energy storage. By contrast, in the 
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fasted state, a series of metabolic modifications induces net glucose output and 
lipid breakdown in the liver to maintain whole body homeostasis (Viollet et al. 
2006). 
AMP-activated protein kinase (AMPK) is a phylogenetically conserved 
serine/threonine protein kinase that has been proposed to function as a cellular 
energy sensor (Kahn et al. 2005) mediating the cellular adaptation to 
environmental or nutritional stress factors. It is activated when nutrient supply 
is limited, ATP generation is impaired, or cellular energy demand is increased 
(Kemp et al. 2003; Hardie et al. 2003). In the last few years, AMPK has come 
to be regarded as a point of conversion of regulatory signals monitoring 
systemic and cellular energy status. AMPK has a critical role in many 
metabolic processes, and, once activated, AMPK phosphorylates a number of 
proteins that determine increased glucose uptake and metabolism as well as 
fatty acid oxidation and, simultaneously, inhibition of hepatic lipogenesis, 
cholesterol synthesis, and glucose production (Hardie et al. 2004; Kahn et al. 
2005; Hardie 2005) (Figure 5). 
 
 
Figure 5: Role of AMPK in regulating energy balance at the whole-body level. 
Green arrows indicate positive effects, and red lines with bars indicate negative effects. In the 
hypothalamus, activation of AMPK in response to low glucose or leptin levels increases food 
intake; references for other effects of AMPK activation can be found in recent reviews. FA, 
fatty acid. 
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AMPK exists as a heterotrimeric complex consisting of a catalytic subunit α 
and two regulatory subunits β and γ (Hardie et al. 1998) and isoforms of all 
three subunits (α1, α2, β1, β2, γ1, γ2 and γ3) have been identified in mammals 
(Carling 2004). AMPK phosphorylates multiple targets in the liver in order to 
acutely switch on alternative catabolic pathways and switch off anabolic 
pathways (Table 1).  
 
 
 
Table 1: Role Hepatic targets of AMPK. 
 
ACC and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA 
reductase) were the first enzymes shown to be downstream targets for AMPK 
(Hardie et al. 2004). ACC and HMG-CoA reductase are, respectively, key 
enzymes in fatty acid and cholesterol synthesis, known as ATP-consuming 
biosynthetic pathways. ACC is an important rate-controlling enzyme for the 
synthesis of malonyl-CoA, which is both a critical precursor in the biosynthesis 
of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation. 
Inhibition of ACC by AMPK leads to a fall in malonyl-CoA content and a 
subsequent decrease in fatty acid synthesis and increase in mitochondrial fatty 
acid oxidation via the allosteric regulation of carnitine palmitoyltransferase-1 
(CPT-1), which catalyses the entry of long-chain fatty acyl-CoA into 
mitochondria. Accordingly, insulin activates ACC to promote malonyl-CoA 
synthesis by inhibiting AMPK (Witters and Kemp 1992). 
AMPK has been implicated in the control of hepatic glucose and lipid 
homeostasis by many additional effects both on genes and on short-term 
regulation of specific enzymes. In the short-term regulation, AMPK 
phosphorylates and inactivates ACC (acetyl-CoA carboxylase), thus inhibiting 
FA biosynthesis. At the same time, inactivation of ACC decreases malonyl 
CoA concentration, which in turn de-represses CPT1 (carnitine palmitoyl 
transferase 1) and activates FA oxidation (Hardie et al. 1998). In the long term, 
AMPK is thought to regulate hepatic lipogenic gene expression by inhibiting 
transcription factors (Ferre et al. 2003). Indeed, AMPK has been found to 
down-regulate SREBP-1c (sterol-regulatory-element-binding protein-1c) (Zhou 
et al. 2001) and inhibit ChREBP (carbohydrate responsive element-binding 
protein) (Kawaguchi et al. 2002). Thus, in the liver, AMPK coordinates the 
changes in the activity of enzymes of lipid metabolism and regulates the 
partitioning of fatty acid between oxidative and biosynthetic pathways. 
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Recent studies have shown that both Liver Kinase B1 (LKB1) and 
Ca2+/calmodulin-dependent protein kinase kinase-β (CaMKKβ/CAMK2) play 
important roles in phosphorylating and activating AMPK. LKB1 (also known 
as STK11) is a 50 kDa serine/threonine kinase which contains both a kinase 
domain and a nuclear localization signal in its N-terminal region. Germline 
mutations of the LKB1 gene are responsible for the cancer-prone Peutz-Jeghers 
syndrome (Jenne et al. 1998; Boudeau et al. 2003). The majority of Peutz-
Jeghers syndrome missense mutations are located in the region coding for the 
kinase domain and result in the abolition of the enzymatic activity, thus 
disrupting all functions attributed to LKB1. The C-terminal region of LKB1 
contains several post-translational modifications. Five phosphorylation sites 
have been identified in human; two residues are autophosphorylation sites 
(Thr336 and Thr402), and three others (Ser325, Thr363, and Ser428) are 
phosphorylated by upstream kinases (Boudeau et al. 2003). LKB1-Ser428 
phosphorylation is required for both its nuclear export of LKB1 into cytosols, 
in which it forms an active complex with STRAD and MO25 and consequent 
AMPK phosphorylation. Because various stimuli increased the 
phosphorylation of LKB1 at Ser428, it is tempting to speculate that LKB1-Ser428 
phosphorylation might be a common pathway required for AMPK activation 
(Figure 6). LKB1 localization depends on its kinase activity, import into the 
nucleus, and retention within cytoplasm. It has been reported that cytoplasmic 
localization of LKB1 is critical for its normal function (Tiainem et al. 2002; 
Nezu et al. 1999; Boudeau, Baas et al. 2003). Recently, LKB1 was 
demonstrated to phosphorylate and activate the catalytic α-subunit of AMPK at 
its T-loop residue Thr172 in a cell-free system (Woods et al. 2003; Hawley et al. 
2003). The major AMPK kinase activity in liver seems to correspond to LKB1 
since it has been shown that deletion of LKB1 in the liver results in a 
proportional decrease of AMPK phosphorylation at Thr172 rendering AMPK 
insensitive to stimuli which normally activate it (Shaw et al. 2005). Thus, 
LKB1 is a crucial regulator of AMPK activation in muscle and liver cells and 
its activity is of potential importance to understand glucose and lipid 
metabolism.  
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Figure 6: Role of AMPK in regulation of energy balance.  
AMPK is activated by phosphorylation of threonine 172 (Thr-172) within the catalytic a-
subunit, catalysed by upstream AMPK kinases. Previous studies have identified LKB1 and 
CaMKKβ acting upstream of AMPK. LKB1, like AMPK forms a heterotrimeric complex, 
requiring binding of MO25 and STE-20 related adaptor protein (STRAD) for activity, and is 
involved in activation of AMPK in response to an increase in the AMP/ATP ratio. CaMKKβ is 
involved in the Ca2+-dependent activation of AMPK. Following activation, AMPK 
phosphorylates a number of downstream targets with the overall effect of switching-off ATP 
consuming pathways, for example, protein synthesis and fatty acid synthesis, while switching-
on ATP generating pathways, for example, glycolysis and fatty acid oxidation. 
 
Together, LKB1 and AMPK control cell growth in response to environmental 
nutrient changes, which identifies new targets and drugs for cancer therapy, 
including several existing diabetes therapeutics that are known to potently 
activate AMPK. 
Recent work has established a central role of atypical protein kinase Cζ 
(PKCζ), a protein kinase of the AGC family, as a key regulator in LKB1-
dependent AMPK activation. Inhibition of PKCζ with pharmacological and 
genetic inhibitors effectively blocked AMPK activation caused by ONOO-. 
This AMPK activation pathway was LKB1-dependent, involved LKB1 
phosphorylation at Ser428 within the C-terminal part of LKB1, and led to the 
association of LKB1 with AMPK (Xie et al. 2006). PKCζ-dependent and 
LKB1-mediated AMPK activation might play important roles in regulating not 
only cellular energy metabolism but also signaling pathways that control cell 
growth, differentiation, and survival. 
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1.4.2 Lipogenesis and genes 
 
The past few years have brought a deluge of new data about the 
mechanisms of regulation of lipogenesis by nutrient and hormones. Regulation 
of gene expression by nutrients is an important part of the mechanisms 
allowing mammals to adapt to their nutritional environment. This is especially 
true for enzymes involved in the storage of energy such as the lipogenic and 
glycolytic enzymes in the liver and adipose tissue. These enzymes are acutely 
regulated by post-translational and allosteric mechanisms but are mainly 
controlled on a long-term basis by a modulation of their transcription rate. It is 
clear that transcription factors and some other genes are attractive targets for 
pharmaceutical intervention of disorders such as hypertriglyceridemia and 
obesity.  
It is now well accepted that the transcription factor Sterol Regulatory Element-
Binding Protein-1c (SREBP-1c), itself stimulated by insulin, mediates the 
transcriptional effect of this hormone on the enzymes involved in fatty acid 
synthesis. SREBP family, originally identified as basic helix–loop–helix 
(bHLH) leucine zipper transcription factors, is involved in the regulation of 
genes participating in cholesterol biosynthesis and low-density lipoprotein 
receptor synthesis (Brown and Goldstein 1997; Brown and Goldstein 1999). 
The SREBP family consists of three isoforms: SREBP-1a, SREBP-1c, and 
SREBP-2. Each isoform has a different regulatory mechanism (Horton and 
Shimomura 1999; Shimano 2001; Shimano 2002; Ide et al. 2004). SREBP-1c 
activates transcription of genes involved in fatty acid and triglyceride 
synthesis, such as the genes encoding acetyl-CoA carboxylase, fatty acid 
synthase, Elovl-6, and stearoyl-CoA desaturase. These genes are regulated by 
SREBP-1c, depending on the nutritional conditions for triglyceride storage. 
Intake of energy molecules such as sugars, carbohydrates and saturated fatty 
acids activates SREBP-1c expression, which is eliminated under conditions of 
fasting and starvation. SREBP-1c activates insulin-mediated lipogenesis, 
whereas starvation signals such as glucagon, protein kinase A and AMP-
activated protein kinase inhibit SREBP-1c. Thus, SREBP-1c plays a major role 
in the long-term control of glucose and lipid homeostasis by insulin, through 
the regulation of glycolytic and lipogenic gene expression. 
With the exception of hepatic GK, which is exclusively induced by insulin 
(Magnuson et al. 1989), most of the glycolytic and lipogenic genes are also 
regulated by glucose (Girard et al. 1997; Towle et al. 1997; Vaulont et al. 
2000). Another important protein that plays a critical role in the glucose-
mediated induction of gene products involved in hepatic glycolysis and 
lipogenesis is the glucose-responsive transcription factor ChREBP 
(Carbohydrate response element-binding protein). Glucose affects the activity 
of ChREBP largely through post-translational mechanisms involving 
phosphorylation-dependent cellular localization (Sakiyama et al. 2008). 
ChREBP is a large protein (864 amino acids and 94,600 Da) that contains 
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several domains including a nuclear localization signal (NLS) near the N-
terminus, polyproline domains, a basic loop–helix–leucine-zipper 
(b/HLH/Zip), and a leucine-zipper-like (Zip-like) domain. Glucose activates 
ChREBP by regulating its entry from the cytosol into the nucleus (Dentin et al. 
2005; Kawaguchi et al. 2001) thereby promoting its binding to carbohydrate 
responsive element (ChoRE) present in the promoter regions of glycolytic and 
lipogenic genes (Ishii et al. 2004). Moreover, ChREBP is also regulated by 
glucose at the transcriptional level (Dentin et al. 2004). 
Together ChREBP and SREBP-1c provide a pair of transcription factors that 
functions in synergy through distinct binding response elements to coordinately 
regulate glucose metabolism and lipogenesis (Figure 7). 
 
 
 
Figure 7: SREBP-1c and ChREBP act in synergy to regulate glycolytic and lipogenic gene 
expression. 
The phosphorylation of glucose in glucose 6-phosphate, by hepatic glucokinase, is an essential 
step for glucose metabolism as well as for the induction of glycolytic and lipogenic genes. The 
recent identification of ChREBP has shed light on the possible mechanism whereby glucose 
affects gene transcription. The activity of ChREBP requires a mechanism of 
phosphorylation/dephosphorylation which is determined by the relative activity of protein 
phosphatase 2A (PP2A), regulated by X5P concentrations. SREBP-1c, which is induced by 
insulin, also plays an important role in mediating insulin signaling on lipogenic gene 
expression. These two transcription factors work synergistically to induce transcription of the 
lipogenic genes in the presence of glucose and insulin. 
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An important transcription factor in adipose tissue is the nuclear hormone 
receptor Peroxisome Proliferator-Activated Receptor gamma (PPARγ). This 
protein is part of the adipocyte differentiation program, inducing the 
differentiation of pre-adipocytes into mature fat cells. With respect to the liver, 
although PPARγ is normally only minimally expressed in hepatocytes, hepatic 
triglyceride accumulation is associated with a dramatic increase in PPARγ 
expression, suggesting that the protein may play a role in stimulating 
lipogenesis (Chao et al. 2000). 
As discussed earlier, the state of insulin-resistance at the level of the liver may 
be associated with increased lipogenesis. Recently, several works suggest that 
the family of homeodomain-containing transcription factors named TALE 
(Three Aminoacid Loop Extension) is strongly related to diabetes and insulin-
resistance (Kim et al. 2002; Oriente et al. 2008; Oriente et al. 2011). 
 
 
1.5 TALE proteins 
 
The three-amino acid loop extension (TALE) homeodomain proteins 
are recognized as transcription factors responsible for regulating growth and 
differentiation during vertebrate embryogenesis. The genes encoding these 
proteins are highly conserved and are present in the common ancestor of 
plants, fungi, and animals.  
TALE proteins display a highly conserved DNA binding domain of 
approximately 60 amino acids called the homeodomain (Gehring et al. 1994). 
This region is composed of three alpha helices and a flexible N-terminal arm. 
The homeodomain interacts with the DNA through the third helix making 
base-specific contacts in the major groove of DNA and through the N-terminal 
arm which contacts the minor groove of DNA. Between the first and the 
second alpha helices of the homeodomain there is an extension of three amino 
acids, virtually represented by a proline (P) – tyrosine (Y) – proline (P) in 
position 24-26. This domain has been implicated in important protein–protein 
interactions that are required for fundamental aspects of development. The 
TALE homeodomain superclass is composed of two groups: the PBC and the 
MEIS families. The PBC subclass of the TALE homeodomain proteins, 
referring to the conserved PBC motif N-terminal to the TALE homeodomain 
(Burglin 1997; Burglin 1998), includes the vertebrate Pbx proteins, fly 
Extradenticle and worm Ceh-20. The MEIS class includes Homothorax (Hth) 
in flies and the Meis and Prep proteins in vertebrates (Figure 8) (Moens and 
Selleri 2006).  
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Figure 8: Phylogeny of Hox cofactors. 
TALE homeodomain proteins are divided into two groups: the PBC family, including the 
vertebrate Pbx proteins, fly Extradenticle and worm Ceh-20, and the MEIS family, including 
vertebrate Meis and Prep, fly Homothorax (Hth) and worm Unc-62. Orange letters indicate 
mouse proteins, purple lettering indicates their zebrafish orthologs. Although in some cases the 
orthology assignments are not clear (as for pbx2 and pbx4), genetic rescue experiments in 
zebrafish have suggested that the different pbx genes are functionally identical. Similar 
information is not yet available with regard to mammalian Pbx genes. 
 
Cooperative function among TALE family members is critical for transcription 
regulation (Bischof et al. 1998; Chang et al. 1997; Knoepfler et al. 1997), and 
several members have been shown to function as essential contributors to Hox-
mediated developmental programs (Chan et al. 1994; Mann and Chan 1996; 
Rauskolb and Wieschaus 1994). 
 
 
1.5.1 Pbx1 protein 
 
Pbx1 (pre-B cell leukemia transcription factor) protein is a small 
ubiquitous molecule which belongs to the PBC family. The proto-oncogene 
PBX1 was identified as one of the loci affected in the t(1;19) translocation 
found in a quarter of all pediatric pre-B-cell acute lymphoblastic leukemias 
(Kamps et al. 1990; Nourse et al. 1990). This translocation results in 
expression of a fusion protein consisting of the activation domains of E2A and 
most of Pbx1, including its homeodomain. 
In mice, the individual contribution of each member of PBC family seemed to 
be different because, whereas the Pbx1 single mutant had a wide range of 
malformations, only minor or no phenotypes were obvious in Pbx2 and Pbx3 
mutants suggesting an important role for Pbx1 in the embryonic development. 
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Pbx1 protein is characterized by the homeodomain region including the three 
aminoacid loop extension which interacts with the specific sequences of the 
HOX transcription factors or the Pancreatic and Duodenal homeobox-1 
transcription factor (PDX-1). Near the amino terminal region there are two 
higly homologous regions named PBC- A and –B important for the protein-
protein interaction (Figure 9) (Burglin 1997; Piper et al. 1999; Moens and 
Selleri 2006). The primary interaction between Pbx and HOX is via the three 
amino acid loop in the Pbx homeodomain, which binds a tryptophan-
containing hexapeptide motif (N-Y/F-P/DW-M-K/R) N-terminal to the 
homeodomain in HOX proteins. 
Genetic studies indicate the role of TALE homeodomain protein Pbx1 in the 
development and function of pancreatic islets, which contain the insulin 
secreting β-cells required for maintaining normal glucose homeostasis. Pbx1 is 
required in the developing pancreas for cell growth and differentiation and its 
relevance has been underlined by several studies involving knock-out mice. 
Pbx1−/− embryos exhibit pancreatic hypoplasia and marked defects in exocrine 
and endocrine cell differentiation before death at embryonic day (E) 15 or E16. 
Similarly, also PDX-1 is critical for pancreatic development. It is expressed in 
the foregut endoderm at E8.5, prior to the onset of bud formation and 
embryonic deletion of PDX-1 results in pancreatic agenesis (Jonsson et al. 
1994). Examination of Pbx1+/– mice showed that Pbx1 was required for 
pancreatic insulin secretion in mature islets, and that germline Pbx1 
inactivation led to inadequate levels of circulating insulin and impaired glucose 
tolerance, conditions known to presage the onset of overt type 2 diabetes. In 
these animals, the levels of PDX-1 are strongly reduced, indicating that Pbx1 is 
important for its expression and most probably assessing the molecular events 
responsible for the observed phenotype (Selleri et al. 2001; Brendolan et al. 
2005; Kim et al. 2002). Analysis of transheterozygous Pbx1+/−/Pdx1+/− mice 
revealed in vivo genetic interactions between Pbx1 and Pdx1 that are essential 
for postnatal pancreatic function and regulate islet structure and function. 
Consequently, simultaneous haploinsufficiency for Pbx1 and Pdx1 resulted in 
an oligogenic mouse model of age-dependent diabetes mellitus (Kim et al. 
2002). Similarly, a Pbx interaction-defective Pdx1 transgene is unable to rescue 
normal glucose homeostasis in Pdx1 null mice (Dutta et al. 2001).  
The other class of TALE proteins, the MEIS transcription factors, interacts 
with PBC proteins, participating in ternary complexes with Hox proteins, or 
modulating PBC protein stability and subcellular localization. 
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Figure 9: Structure of TALE homeodomain proteins.  
Prototype members of PBC and MEIS classes are shown here. ‘‘a’’ and ‘‘b’’ refer to splice 
isoforms of Pbx and Meis proteins. All TALE homeodomain proteins contain a divergent 
homeodomain (HD) containing a 3 amino acid loop extension (TALE) between the first and 
second a-helices. The TALE motif virtually always bears a proline (P)– tyrosine (Y)– proline 
(P) in positions 24– 26 and contacts the hexapeptide motif of Hox proteins. Pbx proteins 
contain an additional DNA-contacting a-helix (a4; HCM) C-terminal to the canonical 
homeodomain. The PBC-A and PBC-B domains are conserved among Pbx, Exd and Ceh-20, 
and the PBC-A domain interacts with Meis/Prep proteins (Ryoo et al., 1999). Conversely, the 
HM1 and HM2 domains are conserved among Meis/Prep proteins and are required for 
interactions with Pbx proteins. Posterior Hox genes of the AbdB subclass are unusual in that 
they can interact directly with Meis proteins via a C-terminal region (CTD) of Meis including 
the homeodomain; this region is indicated by a black bar. 
 
 
1.5.2 Prep1 protein 
 
Prep1 (Pbx regulating protein 1) is a 64 kDa ubiquitary homeodomain 
transcription factor of the three aminoacid loop extension (TALE) superclass of 
proteins mapping on the chromosome 21q.22.3. The Prep1 homeodomain is 
structurally related to the PBC homeodomain class and contains an isoleucine 
residue in the third position of the conserved WF_N sequence in the 
homeodomain. Indeed, Prep1 forms DNA-independent dimeric complexes with 
the Pbx homeodomain transcription factor, enhancing target specificity and 
regulatory function (Berthelsen et al. 1998). Prep1 shares homology with MEIS 
proteins within the homeodomain and in two well-preserved amino terminal 
regions termed HR1 and HR2 (Homology Region) (HM in Figure 9). HR1 and 
HR2 bind the N-terminal region of Pbx1 (PBC-A) and are essential for Prep1-
Pbx1 heterodimerization, which in turn is required for DNA binding 
(Berthelsen et al. 1998). Prep1 could be localized both in cytoplasm and in 
nucleus and the heterodimerization with Pbx1 appears to be essential to 
translocate Prep1 into the nucleus to bind DNA target. On the other hand, 
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Prep1 dimerization prevents nuclear export and the proteasomal degradation of 
Pbx1 prolonging its half-life (Berthelsen et al. 1999). Formation of dimeric 
complex drastically increases binding affinity of Prep1/Pbx1 to the DNA and 
also broadens the DNA target selectivity of Pbx1 to include sequences 
containing the TGACAG sequence (Berthelsen et al. 1998). Together Prep1 
and Pbx1 form the UEF-3 (Urokinase Enhancer Factor-3) transcription factor, 
which is important in regulating the activity of the urokinase plasminogen 
activator (uPA) gene enhancer. The UEF3 DNA target site is a regulatory 
element in the promoters of several growth factor and protease genes, such as 
interleukin-3 (IL-3), stromelysin and urokinase plasminogen activator (uPA) 
(Berthelsen et al. 1996). Prep1 and Pbx1 can form ternary complexes with 
PDX-1 to regulate somatostatin gene transcription (Goudet et al. 1999). 
The role of Prep1 has been in part clarified by the generation of mutant mice. 
Nevertheless, Prep1 null embryos results in early lethality before gastrulation 
(E7.5) (Fernandez-Diaz et al. 2010), precluding a study of the Prep1 role in 
later developmental processes. An insertion of a retroviral vector in the first 
intron of the Prep1 gene results  in a hypomorphic mutation (Prep1i/i) that 
exhibits variable penetrance and expressivity. Prep1i/i embryos die between 
E17.5 and P0 and present a profound alteration in the hematopoietic 
development with a deficient radioprotection activity of fetal liver (FL) 
progenitors and all colony-forming progenitors and profound anemia (Ferretti 
et al. 2006). However, a small percentage of the Prep1i/i embryos are born alive 
and subsequently live a normal length-life. The mice escaping embryonic 
lethality show T-cell development anomalies with a decreased number of 
circulating CD4+ and CD8+ T cells and increased apoptosis (Penkov et al. 
2005). In addition, Prep1i/i feature an impairment of erythropoiesis and 
angiogenesis accompanied by  liver hypoplasia, decreased hematocrit, anemia, 
and delayed erythroid differentiation together with a decrease in capillary 
formation (Ferretti et al. 2006). These mice show also alterations in eye 
development, in fact in most cases the size of the lens is strongly reduced, 
similar to the phenotype of Pax6-deficient mice. Prep1 deficiency affects the 
expression of both TALE class partners Pbx and Meis, both required for 
embryonic hematopoiesis (Azcoidia et al 2005; Di Martino et al. 2001; Hisa et 
al. 2004).  
 
 
1.5.3 Prep1 and insulin-resistance 
 
In our laboratory we have recently evidenced an important role of Prep1 
in pancreas development, glucose homeostasis and regulation of insulin-action 
in muscle and liver (Oriente et al. 2008; Oriente et al. 2011).  
Prep1-hypomorphic mice show smaller pancreatic islet but normal 
architecture. However, these mice feature islet hypoplasia, accompanied by 
significantly reduced absolute insulin levels (both basal and postloading). The 
Prep1i/i phenotype includes also a strong reduction of pancreatic Pbx1 
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expression, emphasizing the idea that Prep1 hierarchically acts upstream in the 
network regulating pancreas development by controlling the levels of Pbx1. 
Moreover, these mice exhibit protection from streptozotocin-induced diabetes 
and enhanced insulin sensitivity with improved glucose uptake and insulin-
dependent glucose disposal by skeletal muscle. This muscle phenotype does 
not depend on reduced expression of Pbx1, rather than on reduced levels of the 
recently identified novel Prep1 interactor p160 Myb-binding protein (p160MBP), 
a molecule which is known to inhibit the PGC-1α-mediated glucose transport 
and competes with Pbx1 to bind Prep1. Consistent with p160MBP decrease, 
these mice show a muscle-selective increase in mRNA and protein levels of 
PGC-1α, accompanied by enhanced expression of the GLUT4 transporter and 
glucose uptake in muscle. These effects have been confirmed by transfecting 
Prep1, Pbx1 and p160MBP cDNA in differentiating L6 skeletal muscle cells. 
Overexpression of Prep1 stabilizes p160MBP, inducing p160MBP escape from 
proteasomal  and reduces the levels of PGC-1α and GLUT4.  
The mechanisms responsible for Prep1 action in liver differ from those in the 
skeletal muscle since Pbx1 and p160MBP are expressed at different levels. In 
fact, while there is a marked reduction of p160MBP in the skeletal muscle of the 
hypomorphic mice compared to the wild type animals, this difference has not 
detectable in the liver because in this organ the expression of p160MBP is very 
low. Thus, at variance with muscle, Prep1 major functional partner in liver 
appears to be Pbx1 rather than p160MBP.  
Prep1 deficiency in animal models improves insulin signaling in liver 
increasing hepatic glycogen content and decreasing glucose output and 
triglyceride levels. Analysis of the initial steps in insulin signaling in the 
Prep1-deficient mouse liver revealed increased tyrosine phosphorylation of 
both insulin receptor and the major IRSs present in these cells. These effects 
are paralleled by a significant reduction of expression of SYP and SHP1 
tyrosine phosphatases. The functional relevance of Prep1 control of SHP1 
versus SYP expression to hepatic sensitivity to insulin was assessed in further 
experiments in HepG2 liver cells stable transfected with Prep1. These cells 
feature a very significant reduction of insulin effect on glycogen accumulation. 
In particular, expression of SHP1 in cellular models negatively correlates with 
insulin signaling. However, antisense silencing of SHP1 rescued insulin effect 
in these cells, thus establishing SHP1 as the functionally relevant target of 
Prep1 in the liver. The regulatory region of SHP1 gene contains several Prep1 
binding sites in the 4,000 base-pair region upstream SHP1 transcription 
initiation site and one Prep1/Pbx1 binding site responding to the ectopic 
expression of Prep1 and Pbx1 in cotransfection experiments in vitro. In these 
assays, a fragment containing single Prep1/Pbx1 binding site displays a 
powerful enhancer function. Thus, Prep1-Pbx1 complex enhances SHP1 gene 
transcription by acting on regulatory sequences upstream the ATG codon. 
On the basis of the results, Prep1 might be considered as a new gene involved 
in the pathogenesis of type 2 diabetes and insulin-resistance. 
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1.6 Tyrosine and lipid phosphatases 
 
Insulin signaling cascade may be attenuated by several enzymes, like 
for example the protein tyrosine phosphatases (PTPases), which catalyse the 
rapid dephosphorylation of the receptor and its substrates. Several PTPases, as 
the tyrosine phospatases PTP-1B, SYP and SHP1 and the lipid phosphatases 
SHIP2 and PTEN, are expressed in insulin-responsive cells and are up-
regulated in states of insulin-resistance. 
The Protein Tyrosine Phosphatese 1B (PTP1B) is a major regulator of insulin 
sensitivity and body fat content and deletion of its gene leads to increased 
insulin sensitivity and resistance to obesity induced by high fat feeding (Cheng 
et al. 2002; Johnson et al. 2002; Elchebly et al. 1999; Klaman et al. 2000). 
SYP is a widely expressed PTP and its overexpression in a transgenic mouse 
model induces insulin-resistance (Maegawa et al.1999). 
Another PTP recently linked to insulin signaling and glucose metabolism is 
SHP1. Mice expressing a catalytically defective SHP1 are markedly glucose 
tolerant and insulin sensitive compared to wild-type controls, as a result of 
enhanced insulin receptor signaling to IRS-PI3K-Akt in liver and muscle 
(Dubois et al. 2006). 
Insulin pathway can be regulated by other phosphatases, the lipid phosphatases. 
Insulin activates the phosphoinositide 3-kinase (PI3K) which phosphorylates 
phosphatidylinositol 4,5 bisphosphate transiently generating 
phosphatidylinositol 3,4,5 trisphosphate at the plasma membrane (Czech 
2003). Regulation of the PI3K pathway is critical for the prevention of insulin-
resistance. PtdIns(3,4,5)P3 binds to the pleckstrin homology (PH) domain of 
the AGC family protein kinases, including protein kinaseB (PKB)/Akt, serum- 
and glucocorticoid-induced protein kinase (SGK) and protein kinase C (PKC), 
localizing and activating these kinases (Cantley 2002).  Lipid phosphatases, src 
homology 2 domain containing inositol 5'-phosphatase 2 (SHIP2) and skeletal 
muscle and kidney-enriched inositol phosphatase (SKIP) hydrolyze PI(3,4,5)P3 
to PI(3,4)P2 and phosphatase and tensin homolog deleted on chromosome ten 
(PTEN) hydrolyzes PI(3,4,5)P3 to PI(4,5)P2. 
SH2-containing inositol 5’-phosphatase 2 (SHIP2) is a lipid phosphatase that 
contributes to the negative regulation of insulin signaling specifically via its 5'-
phosphatase activity. A SHIP2 knockout mouse has been recently reported, 
generated by deleting the first 18 exons of the SHIP2 gene which encodes the 
SH2 domain and catalytic 5-phosphatase domain, leaving exons 19–28 intact 
(Sleeman et al., 2005). On a normal diet the serum triglycerides, non-esterified 
free fatty acids cholesterol and leptin levels are decreased in SHIP2−/− mice, 
although the basal metabolic rate is the same as wild type litter mate controls. 
Significantly, SHIP2−/− mice do not become obese on a high fat diet, showing 
an increased metabolic rate and inability to increase body fat, but no increase in 
serum lipids, insulin or glucose levels under obesity inducing conditions. In 
addition, polymorphisms in the human SHIP2 gene are associated, at least in 
part, with the insulin resistance of type 2 diabetes. 
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SHIP2 appears to play an important role in the control of glucose and/or energy 
homeostasis by the regulation of the insulin action and emerges as a potential 
target for the treatment of obesity and insulin-resistance.  
Another key negative regulator of the phosphatidylinositol 3-kinase/Akt 
pathway is the lipid phosphatases PTEN (Stambolic et al. 1998). Whole body 
PTEN knockout (KO) mice die at the early stages of embryonic development, 
which prevents study of the role of PTEN in the mammalian insulin signaling 
pathway in a whole animal model (Di Cristofano et al. 1998; Suzuki et al. 
1998). Recent development of a liver-specific PTEN KO mouse exhibiting a 
phenotype of fatty liver and steatohepatitis due to increased lipogenesis and TG 
storage suggests a key role of this phosphatase in hepatic lipid and lipoprotein 
metabolism (Horie et al. 2004; Stiles et al. 2004). 
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2. AIMS OF THE STUDY 
 
Insulin-resistance is a common feature present in a number of 
physiological and pathological conditions in humans and is commonly found in 
a large number of adults, in particular those with android obesity, metabolic 
syndrome or type 2 diabetes. Strong adverse relationships between adipose 
tissue, liver and muscle in these patients determine lipotoxicity, with deposition 
of triglycerides within the liver and muscles together with insulin-resistance. 
Prep1 is an homeodomain transcription factor that, in combination with its 
major partners, Pbx proteins, regulates the overall size of the organism and 
individual organs as well as major developmental pathways. Data produced in 
our lab indicate that Prep1 hypomorphic mice (Prep1i/+) have a complex 
metabolic phenotype characterized by increased insulin sensitivity 
accompanied by protection from streptozotocin-induced diabetes and by the 
presence of smaller but normally structured islets with reduced fasting and 
post-loading plasma insulin levels. In muscle tissue, Prep1 deficiency 
positively modulates the intracellular pool of GLUT4 by enhancing the 
transcription of PGC-1α gene. In the liver, the mechanism is independent on 
PGC-1α and the improvement of insulin signaling is characterized by a 
reduction of tyrosine phosphatases SHP1, whose transcription is mediated by 
the Prep1/Pbx1 complex and by an increase of insulin-stimulated insulin 
receptor and IRS1/2 tyrosine phosphorylation. 
As mentioned before, Prep1i/+ mice show decreased hepatic triglyceride levels 
(Oriente et al. 2011). Whether and how Prep1 affects lipid metabolism in liver 
is unknown at the present, thus the aim of my project has been to investigate 
the role of Prep1 on hepatic lipogenesis. 
To achieve this aim I have studied the main genes involved in the regulation of 
lipid metabolism in the liver of Prep1 hypomorphic mice and focused my 
attention on the possibility that these genes could have been regulated by the 
transcription complex Prep1/Pbx1. Moreover, I have investigated whether the 
overexpression of Prep1 might increase triglyceride synthesis in HepG2 
(hepatoma cells) and confirm the molecular mechanism by which Prep1 acts. 
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3. MATERIALS AND METHODS 
 
3.1 Materials 
 
Media, sera, antibiotics for cell culture and the lipofectamine reagent 
were from Invitrogen (Grand Island, NY). The Prep1, actin, Pbx1, SHP1, 
SHIP2, p-ACC, ACC, AMPK, LKB1, p-CAMK2, CAMK2, p-PKCζ, PKCζ, p-
PKA, PKA antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA). The p-LKB1 and p-AMPK antibodies were from Cell Signaling 
Tecnology, Inc. Protein electrophoresis and Real Time PCR reagents were 
purchased from Bio-Rad (Hercules, CA), Western blotting and ECL reagents 
from Amersham Biosciences (Arlington Heights, IL). Oil Red O stain and all 
other chemicals were from Sigma (St. Louis, MO). 
 
 
3.2 Generation of Prep1 hypomorphic mice 
 
Prep1 targeted mice were generated by gene trapping by Lexikon 
Genetics, Inc. (The Woodlands, Texas) and have been previously described 
(Ferretti et al. 2006; Penkov et al. 2005; Fernandez-Diaz et al. 2010). In the 
experiments reported in this paper, heterozygous mice were backcrossed with 
wild-type (WT) C57BL/6 for 4 generations. All animal handling conformed to 
regulations of the Ethics Committee on Animal Use of H. S. Raffaele (IACUC 
permission number 207). Hepatic tissue samples were collected rapidly after 
mice were sacrificed by pentobarbitone overdose. Tissues were snap frozen in 
liquid nitrogen and stored at –80°C for subsequent western blotting and Real 
Time RT-PCR analysis. 
 
 
3.3 Quantitative assay of serum triglycerides 
 
The blood for serum biochemistry evaluation was collected with a 
intracardiac methods (IC), allowed to clot at room temperature and centrifuged 
for 10 min, then, the serum was separated for shipment. Quantitative analysis 
of serum triglycerides was performed with a ABX Pentra400 clinical chemistry 
analyser using the reagent ABX Pentra Triglycerides CP (ABX-Horiba, 
Montpellier, France) according to the manufacturer's instructions. 
 
 
3.4 Cell culture procedures and transfection 
 
HepG2 hepatoma cells and NMuLi mouse liver cells were cultured at 
37°C in Dulbecco’ s modified Eagle’ s medium (DMEM) supplemented with 
10% fetal bovine serum, 2% L-glutamine, 10,000 units/ml penicillin, 10,000 
g/ml streptomycin. Transient transfection of Prep1, Prep1HR1 and Pbx1 
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plasmid cDNAs or SHIP2 (5’-GCTCTCTAGTTCCTGCTCCC-3’) and SHP1 
(5’-GAGGTCTCGGTGAAACCACCTCACCATCCT-3’) phosphorothioate 
antisense oligonucleotides or scrambled control oligonucleotides SHIP2 (5’-
TCGCCACGTCGCTCATTGTT-3’)  and SHP1 (5’-GTAGAGTTCCGTGAG 
ACACCTCTCCACCAC-3’) were performed by the Lipofectamine and 
Oligofectine reagent according to the manufacturer’s instruction. For these 
studies, 60-80% confluent cells were washed twice with Optimem (Invitrogen) 
and incubated for 8h with 3-5 g of plasmid construct or with 250nM of 
oligonucleotides and 45-60 µl of lipofectamine reagent. In transient 
transfection, the medium was then replaced with DMEM with 10% fetal bovine 
serum and cells further incubated for 15 h before being assayed. In stably 
transfection individual G418-resistant clones were selected by the limiting 
dilution technique (G418 effective dose, 0.8 mg/ml). 
 
 
3.5 Oil Red O staining 
 
To measure cellular neutral lipid droplet accumulation, HepG2 cells 
were stained by the Oil Red O method. HepG2 cells were grown in a p60 plate 
and trasfected with Prep1, Prep1HR1 and Pbx1 plasmid cDNAs. After 48h cells 
were washed three times with iced PBS and fixed with 4% parafolmaldeide for 
30 minutes. After fixation, cells were washed three times and stained with Oil 
Red O solution (working solution, 0.5g Oil Red O powder Sigma dissolved in 
60% ethanol) for 15 min at room temperature. Cells were washed again with 
phosphate-buffered saline (PBS) to remove unbound staining. The HepG2 cells 
were examined under a light microscope, and the red oil droplets stained in the 
cells indicate TG accumulation. 
 
 
3.6 Western blot analysis  
 
Tissue samples were homogenized in a Polytron (Brinkman 
Instruments, N.Y.) in 20 ml T-PER reagent/gram of tissue according to 
manufacture (Pierce, IL). After centrifugation at 10,000 rpm for 5 minutes, 
supernatant was collected. Cells were solubilized in lysis buffer (50 mmol/l 
HEPES, pH 7.5, 150 mmol/l NaCl, 10 mmol/L EDTA, 10 mmol/l Na4P2O7, 2 
mmol/L Na3VO4, 100 mmol/L NaF, 10% glycerol, 1% Triton X-100, 1 
mmol/L PMSF, 10 mg/ml aprotinin) for 1 h at 4C and lysates were centrifuged 
at 5,000g for 20 min. Total homogenates were separated by SDS-PAGE and 
transferred on 0.45 m Immobilon-P membranes. Upon incubation with primary 
and secondary antibodies, immunoreactive bands were detected by ECL 
according to the manufacturer's instructions. 
 
 
 
33 
 
3.7 Real-Time RT-PCR analysis 
 
Total cellular RNA was isolated from liver and HepG2 cells by using 
the RNeasy kit (QIAGEN Sciences, Germany), according to manufacturer’s 
instructions. 1 µg of tissue or cell RNA was reverse-transcribed using 
Superscript III Reverse Transcriptase (Invitrogen, CA). PCR reactions were 
analyzed using SYBR Green mix (Bio-Rad, Hercules, CA). Reactions were 
performed using Platinum SYBR Green qPCR Super-UDG using an iCycler IQ 
multicolor Real Time PCR Detection System (Bio-rad, Hercules, CA). All 
reactions were performed in triplicate and β-actin was used as an internal 
standard. Primer sequences used were as follows:  
mFAS F:5'-ACGACAGCAACCTCACGGCG-3', R:5' CTGCAGAGCCCGTG 
CCAGAC-3'; mACC F: 5'-CCTGGAGTGGCAGTGGTCTTCG-3', R: 5'-TCC 
TCCTCCCTCTGAGGCCTTG-3'; mSHIP2 F: 5'-TCAGATGTGGAGGACGA 
GAAG-3', R: 5'-TGCTGGAGTTGTGGGAGTC-3';  hPrep1 F: 5’-GGAGTGC 
CAACCATGTTAAGAAGAAGTCCC-3’, R: 5’- GACACCGTGTGCTTCTC 
GCTCAAG-3’; hFAS F: 5'-GAGAGCCTCTTCTCCAGGGT-3', R: 5'-CTTCA 
GAGACTCCACCCAGC-3'; hACC F: 5'-TGTCAATCTTGAGGGCTAGG 
TC-3', R: 5'-TGAATCGAGAGTGCTGGTTC-3'; hSHIP2 F: 5’-ATCCTG 
GTTCACATCGAAGG-3’, R: 5’-GCGGTAATCCAGATCCGTAA-3’. 
 
 
3.8 Chromatin immunoprecipitation (ChIP) and Re-ChIP assay 
 
The cross-linking solution, containing 1% formaldehyde, was added 
directly to cell culture media. The fixation proceeded for 10 min and was 
stopped by the addition of glycine to a final concentration of 125 mM. nMuLi 
cells were rinsed twice with cold phosphate buffered saline plus 1 mM 
phenylmethylsulfonyl fluoride and then scraped. Cells were collected by 
centrifugation at 800 X g for 5 min at 4 °C. Cells were swelled in cold cell 
lysis buffer containing 5 mM PIPES (pH 8.0), 85 mM KCl, 0.5% Nonidet P-
40, 1 mM phenylmethylsulfonyl fluoride, and inhibitors mixture (Sigma) and 
incubated on ice for 10 min. Nuclei were precipitated by microcentrifugation at 
2000Xg for 5 min at 4 °C, resuspended in nuclear lysis buffer containing 50 
mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.8% SDS, 1 mM 
phenylmethylsulfonyl fluoride and inhibitors mixture (Sigma), and then 
incubated on ice for 10 min. Samples were broken by sonication into chromatin 
fragments of an average length of 500/ 1000 bp and then microcentrifuged at 
16,000 X g for 10 min at 4 °C. The sonicated cell supernatant was diluted 8-
fold in chromatin immunoprecipitation (ChIP) dilution buffer containing 
0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris- HCl (pH 8.0), 
and 167 mM NaCl and precleared by adding salmon sperm and conjugating 
protein at equimolar concentration for 90 min at 4 °C. Precleared chromatin 
from 1X106 cells was incubated with 1 g of polyclonal antibody (anti-Prep1) 
or no antibody and rotated at 4 °C for 16 h. Rabbit IgG antibody (Upstate 
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Biotecnology/Millipore) was used as a non-specific antibody control. 
Immunoprecipitates were washed five times with radioimmune precipitation 
assay buffer containing 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1% Triton X-
100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, and 1 mM 
phenylmethylsulfonyl fluoride, twice with LiCl buffer containing 0.25 M LiCl, 
1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl 
(pH 8.0), and then 3 times with TE (10 mM Tris-HCl (pH 8.0), 1 mM EDTA). 
Before the first wash, the supernatant from thereaction lacking primary 
antibody was saved as total input of chromatin and was processed with the 
eluted immunoprecipitates beginning at the cross-link reversal step. 
Immunoprecipitates were eluted by adding 1% SDS, 0.1 M NaHCO3, and 
reverse cross-linked by the addition of NaCl to a final concentration of 200 
mM and by heating at 65 °C for at least 4 h. Recovered material was treated 
with proteinase K, extracted with phenol-chloroform-isoamyl alcohol 
(25:24:1), and precipitated. The pellets were resuspended in 30 l of TE and 
analyzed by PCR using specific primers for the analyzed regions. The input 
sample was resuspended in 30 l of TE and diluted 1:10 before PCR. For 
ReChIP assay, immunoprecipitates with the first antibody were eluted in 50 ml 
of DTT 10 mM, diluted 10-fold in ChIP Dilution Buffer supplemented with 
protease inhibitors, and immunoprecipitated with the second antibody (anti-
Pbx1). Following immunoprecipitation, samples are processed as described 
above for ChIP assay and eluted DNA amplified by PCR with specific oligos: 
seq n°1 F: 5’-CACATTCCCTATTCCCATCA-3’, R: 5’-AGGCTAGAGGG 
TGCTTCTGC-3’; seq n°2 F: 5’-AGCTCTCTCCTTCCACCACA-3’, R: 5’-GA 
GGCAGAAGCAAATGGAAC-3’. 
 
 
3.9 Statistical procedures 
 
Data were analysed with the Statview software (Abacus-concepts) by 
one-factor analysis of variance. P values of less than 0.05 were considered 
statistically significant. 
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4. RESULTS 
 
4.1 Hepatic lipid metabolism in Prep1-deficient mice 
 
To study the role of Prep1 on hepatic lipogenesis, I first measured 
serum triglyceride (TG) content in Prep1i/+ mice and in control littermates 
(wild type). As shown in figure 10A serum TG levels were reduced by 33% in 
Prep1i/+ mice compared to the wild type mice. This result was consistent with 
our previous data showing a marked decrease of hepatic triglyceride content in 
the hypomorphic mice (Oriente et al. 2011).  
To investigate in detail this issue, I focused my attention on the metabolic 
pathway that leads to the synthesis of triglycerides in the liver by measuring 
FAS mRNA levels. Consistent with the decrease of TG content, Prep1 
hypomorphic mice showed a 62% reduction of FAS mRNA levels compared to 
control mice (Figure 10).  
 
 
 
Figure 10: Serum triglyceride content and  FAS mRNA levels in Prep1i/+ mice. 
A: Serum triglyceride content was measured using ABX Pentra400 clinical chemistry analyser 
as described in Materials and Methods. B: The abundance of FAS mRNA was determined by 
real-time RT-PCR analysis of total RNA isolated from the liver of hypomorphic and control 
mice, using β-actin as internal standard. Bar represents the mean ± SD of four independent 
experiments, in each of which reactions were performed in triplicate using the pooled total 
RNAs obtained from six mice per genotype. Asterisks denote statistically significant 
differences (**P < 0.01).  
 
Next, I evaluated the phosphorylation and the expression of AMPK, one of the 
main molecules involved in regulation of hepatic lipogenesis. In parallel with 
the pattern of change FAS expression, Thr172-phosphorylated AMPK (p-
AMPK), was diminished in Prep1i/+, while no differences were detected in 
AMPK protein levels. In addition, ratio of phospho-AMPK to total AMPK 
increased by 3-fold in Prep1 heterozygous mice (Figure 11). 
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Figure 11: AMPK phosphorylation and expression in Prep1i/+ mice. 
Liver from Prep1 hypomorphic and control mice were dissected, solubilized, and protein 
samples analyzed by Western blot with p-AMPK and AMPK antibodies. Actin antibody was 
used for normalization. Blot were revealed by ECL and autoradiograph subjected to 
densitometric analysis. The autoradiograph shown on the top of the graphic is representative of 
four independent experiments. Asterisks denote statistically differences (**P < 0.01). 
 
The increased AMPK threonine phosphorylation in Prep1i/+ animals prompted 
me to explore the molecular status of ACC, the principal AMPK downstream 
kinase. Western blot analysis (Figure 12A) showed a significant increase in 
ACC-Ser79 phosphorylation in heterozygous mice. As for AMPK, the ratio of 
phosphorylated ACC to total ACC was elevated by 2.5-fold. Both ACC protein 
and mRNA levels did not change (Figure 12A, B). 
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Figure 12: ACC phosphorylation and expression in Prep1i/+ mice. 
A: Tissues from Prep1 hypomorphic and control mice were dissected, solubilized, and protein 
samples analyzed by Western blot with p-ACC and ACC antibodies. Actin antibody was used 
for normalization. Blot were revealed by ECL and autoradiograph subjected to densitometric 
analysis. The autoradiograph shown on the top of the graphic is representative of three 
independent experiments. Asterisks denote statistically differences (*P < 0.05). B: The 
abundance of ACC mRNA was determined by real-time RT-PCR analysis of total RNA 
isolated from the liver of hypomorphic and control mice, using β-actin as internal standard. Bar 
represents the mean ± SD of three independent experiments, in each of which reactions were 
performed in triplicate using the pooled total RNAs obtained from six mice per genotype. 
 
 
4.2 Prep1 effect on the AMPK-mediated lipogenesis regulation in mouse 
liver 
 
To investigate the molecular mechanisms of AMPK activation, I 
studied the activation and the protein levels of several protein kinases involved 
in the regulation of hepatic lipogenesis. In particular, I measured the activation 
of two upstream molecules of AMPK signaling, the Liver Kinase B1 (LKB1) 
and the Calcium/calmodulin-dependent protein kinase type II (CAMK2). In 
parallel with AMPK and ACC, LKB1, but not CAMK2, phosphorylation, 
increased by 2.9-fold in Prep1i/+ mice compaired to the wild type. No 
differences were detected in total levels of both the serine/threonine kinases 
(Figure 13A, B). These results demonstrated that the activation of AMPK in 
Prep1 hypomorphic mice may occur through the LKB1 pathway. Several 
authors have established a central role of atypical protein kinase Cζ (PKCζ) or 
protein kinase A (PKA) as key regulators in LKB1-dependent AMPK 
activation. As shown in figure 13C, PKCζ phosphorylation and ratio of 
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phosphorylated PKCζ to total PKCζ were significantly elevated in the 
heterozygous animals with no change of protein levels. In contrast, PKA 
featured no difference between WT and Prep1i/+ mice (Figure 13D). These 
results suggest to me that the reduction of TG levels in the Prep1i/+ could 
depend on a mechanism involving PKCζ, LKB1 and AMPK. 
 
 
 
 
Figure 13: LKB1, CAMK2, PKCζ and PKA phosphorylation and expression in Prep1i/+ 
mice. 
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Livers from Prep1 hypomorphic and control mice were dissected, solubilized, and protein 
samples analyzed by Western blot with p-LKB1 and LKB1 (A), p-CAMK2 and CAMK2 (B), 
p-PKCζ and PKCζ (C), p-PKA and PKA (D) antibodies. Actin antibodies were used for 
normalization. Blot were revealed by ECL and autoradiograph subjected to densitometric 
analysis. The autoradiograph shown on the top of the graphic is representative of four 
independent experiments. Asterisks denote statistically differences (**P < 0.01; ***P < 0.001). 
 
 
4.3 Prep1 regulates triglyceride synthesis in HepG2 cells 
 
To further examine Prep1 action on triglyceride synthesis and on 
regulation of AMPK-mediated pathway, I have transiently transfected a Prep1 
cDNA in the HepG2 hepatoma cells (Figure 14A) and triglycerides 
accumulation was analyzed by microscopy after staining of cells with Oil Red 
O. In Prep1 overexpressing cells, lipid droplets were clearly observed with 
light red cytoplasmic staining. In contrast, I barely noted visible lipid droplets 
in cells transfected with an empty vector (Figure 14B). Consistent with these 
data, also FAS mRNA levels were increased by 50% in Prep1 overexpressing 
cells (Figure 14C). 
 
 
Figure 14: Effect of the overexpression of Prep1 on TG accumulation and on FAS 
expression in HepG2 cells. 
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A: HepG2 cells were transiently transfected with Prep1 cDNA. Cells were then solubilized and 
lysates were analyzed by immunoblotting with Prep1 antibodies and autoradiography to verify 
the transfection. Actin antibodies were used for normalization. The autoradiograph shown is 
representative of different experiments. B: HepG2 cells were stained with Oil Red O as 
described in Material and Methods. The photograph shown is representative of five 
independent experiments. C: The levels of FAS mRNA in cells transfected with the Prep1 
cDNA was quantitated by real-time RT-PCR analysis, using β-actin as internal standard. Bars 
represent the mean ± SD of four independent experiments. Asterisks denote statistically 
significant differences (*P < 0.05). 
 
Thus, I looked at the AMPK signaling. Prep1 transfection downregulated 
AMPK and ACC phosphorylation by 40 and 50%, respectively, without 
changing their protein levels (Figure 15A). Also ACC mRNA expression was 
not modulated by Prep1 (Figure 15B). In parallel, Prep1 overexpression caused 
a > 50% reduction of both LKB1 and PKCζ phosphorylation, confirming the 
data obtained in Prep1i/+ mice (Figure 15A). 
 
 
 
 
Figure 15: PKCζ, LKB1, AMPK and ACC phosphorylation and expression in HepG2 
overexpressing Prep1. 
A: HepG2 cells transiently overexpressing Prep1 were lysed and analyzed by Western blot 
with p-PKCζ, PKCζ, p-LKB1, LKB1, p-AMPK, AMPK, p-ACC and ACC. Actin antibodies 
were used for normalization. The autoradiograph shown is representative of five independent 
experiments. B: The levels of ACC mRNA in cells transfected with the Prep1 cDNA was 
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quantitated by real-time RT-PCR analysis, using β-actin as internal standard. Bars represent the 
mean ± SD of three independent experiments. 
 
 
4.4 SHP1 and SHIP2 mediate the effect of Prep1 on triglyceride synthesis 
 
Previously our work has demonstrated that in liver transcriptional 
activation of SHP1 gene by Prep1 attenuates insulin signal transduction and 
reduces glucose storage. Given that PKCζ is a downstream substrate of the 
insulin receptor, I have transiently transfected a Prep1 full-length cDNA in the 
HepG2 cells. Several clones were obtained and I chose the HepG2Prep1c clone 
overexressing Prep1 by 5-fold compared to wild type HepG2 cells and 
featuring a 3-fold increased expression of SHP1 (Oriente et al. 2011). Transient 
trasnsfection of the HepG2Prep1c cells with phosphorothioate antisense 
oligonucleotides specific for SHP1 (SHP1-AS) silenced SHP1 expression by 
50% (Figure 16A), but induced a modest increase of PKCζ, LKB1, AMPK and 
ACC phosphorylation and reduced FAS mRNA expression by 30% (Figure 
16A, B).  
 
 
 
Figure 16: Effect of SHP1 antisense oligonucleotides on lipogenesis regulation in HepG2 
cells stable transfected with Prep1. 
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A: HepG2Prep1c cells were transfected with SHP1 (SHP1-AS) specific phophorothioate 
antisense oligonucleotides. The lysates were also analyzed by Western blot with SHP1, p-
PKCζ, PKCζ, p-LKB1, LKB1, p-AMPK, AMPK, p-ACC, ACC and actin. The 
autoradiographs shown are representative of four independent experiments. B: The levels of 
FAS mRNA in HepG2Prep1c transfected with the SHP1-AS were quantitated by real-time RT-
PCR analysis, using β-actin as internal standard. Bars represent the mean ± SD of four 
independent experiments. Asterisks denote statistically significant differences (*P < 0.05). 
 
Thus, I looked at the possible involvement of other phosphatases. Several 
authors have shown that the lipid phosphatase SHIP2 attenuates 
phosphatidylinositol 3,4,5-trisphosphate levels generated by PI3-kinase 
reducing the activation of the PI3K substrate PKCζ (Cantley et al. 2002). To 
study a possible regulation by Prep1, I have measured the levels of SHIP2 in 
the liver of the Prep1 heterozygous mice. As shown in figure 17A, SHIP2 was 
reduced by 40% and 50% in these mice compared to controls, respectively at 
the protein and the mRNA levels. In addition, Prep1 transfection in HepG2 
cells induced a 2-fold increase of both SHIP2 protein and mRNA expression 
(Figure 17B). 
 
 
 
Figure 17: SHIP2 expression in Prep1i/+ mice and in HepG2 overexpressing Prep1. 
A: SHIP2 protein abundance was measured by Western blot on hepatic tissues from 
hypomorphic and control mice using specific antibodies. Actin antibodies were used for the 
normalization. Each bar represents the mean ± SD of duplicate determinations in ten mice per 
group. The abundance of SHIP2 mRNA was determined by real-time RT-PCR analysis of total 
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RNA isolated from the liver of hypomorphic and control mice, using β-actin as internal 
standard. Bar represents the mean ± SD of four independent experiments, in each of which 
reactions were performed in triplicate using the pooled total RNAs obtained from six mice per 
genotype. B: Lysates from HepG2 cells overexpressing Prep1 cDNA were blotted with SHIP2 
antibodies, followed by ECL and densitrometry. Actin antibodies were used for normalization.  
Each bar represents the mean ± SD of duplicate determinations in four independent 
experiments. The levels of SHIP2 mRNAs in cells transfected with Prep1 cDNA was 
quantitated by real-time RT-PCR analysis, using β-actin as internal standard. Each bar 
represents the mean ± SD of duplicate determinations in four independent experiments. 
Asterisks denote statistically significant differences (**P < 0.01; ***P < 0.001). 
 
To explore the significance of SHIP2 lipid phosphatase to Prep1 regulation of 
hepatic lipogenesis, I have transiently transfected the HepG2Prep1c clone with 
phosphorothioate antisense oligonucleotides specific for SHIP2 (SHIP2-AS) 
reducing SHIP2 levels by 75% (Figure 18A). Treatment with SHIP2-AS 
increased PKCζ  and LKB1 phosphorylation by 6.4- and 5-fold respectively. 
Also the amount of phosphorylated AMPK and ACC were induced by 4.2- and 
6-fold in presence of SHIP2-AS, while, at variance, no change in the amount of 
these proteins were observed (Figure 18A). Importantly, FAS mRNA 
expression was downregulated by 60% after depletion of SHIP2 (Figure 18B). 
 
 
 
Figure 18: Effect of SHIP2 antisense oligonucleotides on lipogenesis regulation in HepG2 
cells stable transfected with Prep1. 
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A: HepG2Prep1c cells were transfected with SHIP2 (SHIP2-AS) specific phophorothioate 
antisense oligonucleotides. For control, lysates were blotted with SHIP2 or actin antibodies. 
The lysates were also analyzed by Western blot with p-PKCζ, PKCζ, p-LKB1, LKB1, p-
AMPK, AMPK, p-ACC and ACC. The autoradiographs shown are representative of four 
independent experiments. B: The levels of FAS mRNA in HepG2Prep1c transfected with the 
SHIP2-AS were quantitated by real-time RT-PCR analysis, using β-actin as internal standard. 
Bars represent the mean ± SD of four independent experiments. Asterisks denote statistically 
significant differences (***P < 0.001). 
 
 
4.5 Prep1 regulation of SHIP2 gene transcription 
 
Next, I examined the possibility that Prep1 could directly regulate 
SHIP2 gene function. Bioinformatic analysis revealed the presence of two 
potential binding sites for Prep1 and Pbx1 in the 4,000 base pair region 
upstream the ATG codon of SHIP2 gene. Thus, first I evaluated the role of 
Pbx1 on hepatic triglycerides synthesis. Previously our work has shown that 
Prep1 upregulated Pbx1 levels in HepG2 cells (Oriente et al. 2011). 
Interestingly, transfection of Pbx1 significantly increased cellular lipid droplets 
compared with control. In contrast, the Prep1HR1 mutant cDNA, which is 
unable to bind Pbx1 (Diaz et al. 2007), had no effect on lipid accumulation 
(Figure 19A). Also FAS mRNA expression was induced by Pbx1 but not by 
Prep1HR1 mutant (Figure 19B). Consistent with these results, overexpression 
of Pbx1 cDNA in HepG2 cells mimicked Prep1 effects on the phosphorylation 
of PKCζ, LKB1, AMPK and ACC. At opposite, Prep1HR1 mutant failed to 
elicit these effects (Figure 19C). This indicates that the Prep1-Pbx1 dimer 
might control lipogenesis in liver cells. 
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Figure 19: Effect of the overexpression of Pbx1 and Prep1HR1 on TG accumulation and on 
FAS expression in HepG2 cells.  
A: HepG2 cells were transiently transfected with Pbx1 and Prep1HR1 cDNA. Cells were then 
stained with Oil Red O as described in Material and Methods. The photograph shown is 
representative of four independent experiments. B: The levels of FAS mRNA in cells 
transfected with the Pbx1 and Prep1HR1 cDNA was quantitated by real-time RT-PCR analysis, 
using β-actin as internal standard. Bars represent the mean ± SD of four independent 
experiments. Asterisks denote statistically significant differences (**P < 0.01). C: HepG2 cells 
transiently overexpressing Pbx1 and Prep1HR1 were lysed and analyzed by Western blot with 
p-PKCζ, PKCζ, p-LKB1, LKB1, p-AMPK, AMPK, p-ACC and ACC. Actin antibodies were 
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used for normalization. The autoradiograph shown is representative of four independent 
experiments.  
 
 
Next, I measured the levels of SHIP2 in HepG2 cells transfected with Pbx1 
cDNA and Prep1HR1 mutant. As shown in figure 20, Pbx1 transfection in 
HepG2 cells induced a 1.8-fold increase of both SHIP2 protein and mRNA 
expression, while I failed to observe a similar effect in presence of the 
Prep1HR1 mutant. 
 
 
Figure 20: SHIP2 expression in HepG2 overexpressing Pbx1 and Prep1HR1. 
Lysates from HepG2 cells overexpressing Pbx1 and Prep1HR1 mutant cDNAs were blotted with  
SHIP2 antibodies, followed by ECL and densitrometry. Actin antibodies were used for 
normalization. Each bar represents the mean ± SD of duplicate determinations in four 
independent experiments. The levels of SHIP2 mRNAs in cells transfected with Pbx1 and 
Prep1HR1 mutant cDNAs was quantitated by real-time RT-PCR analysis, using β-actin as 
internal standard. Each bar represents the mean ± SD of duplicate determinations in four 
independent experiments. Asterisks denote statistically significant differences (**P < 0.01) 
 
 
To validate the two regions putatively bound by Prep1 and Pbx1 complex in 
the 4,000 base pair region upstream the SHIP2 transcription initiation site 
(Figure 21A; positions nucleotide [nt] -1,284 to -1,268 and nt -856 to -842), I 
performed chromatin imunoprecipitation (ChIP) and re-chromatin 
immunoprecipitation (re-ChIP) experiments in NMuli mouse liver cell line. By 
ChIP experiments the two sites bound Prep1 as shown in figure 21B, in 
addition Re-ChIP assays revealed that Pbx1 was simultaneously present at both 
positions (nt -1,284 to -1,268 and nt -856 to -842).  
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Figure 21: Prep1/Pbx1 binding to the SHIP2 DNA sequences. 
A: Schematic representation of 5’ sequences upstream the putative SHIP2 transcription start 
site including the potential binding sites for Prep1 and Pbx1. B: Soluble chromatin was 
prepared from NMuLi mouse liver cells and immunoprecipitated with Prep1 antibodies. Total 
(input) and immunoprecipitated DNAs were amplified using primer pairs covering the 
indicating SHIP2 fragments. Re-ChIP assay with Pbx1 antibodies was performed as described 
under Materials and Methods. 
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5. DISCUSSION 
 
Insulin-resistance increases serum free fatty acid levels, which are taken 
up by the liver and drive triglyceride production and hepatic steatosis. In 
addition, insulin-resistance promotes de novo lipogenesis through upregulation 
of lipogenic transcription factors. Increased FAs might cause the accumulation 
of fat deposits in liver and impair hepatic metabolic functions. 
Several studies have demonstrated the complex relationship between Non 
Alcoholic Steatohepatitis (NASH) and metabolic disorders such as central 
obesity, dyslipidemia and insulin-resistance in both humans and rodents 
(Samuel et al. 2004).  
Previous studies have identified Prep1 as a physiologic regulator of insulin-
mediated glucose metabolism both in skeletal muscle and in liver (Oriente et 
al. 2008; Oriente et al. 2011). In Prep1-deficient mice, muscle sensitivity to 
insulin action on glucose disposal is significantly increased, due to 
downregulation of an important Prep1 partner p160MBP and induction of the 
GLUT4 gene activator PGC-1α. In the liver, Prep1 silencing enhances insulin 
signaling, thereby increasing glucose storage and reducing glucose output. 
Indeed, Prep1 hypomorphic mice show increased hepatic glycogen content and 
decreased triglyceride levels. The potential significance of these findings to 
insulin-resistance and diabetes is further underlined by our experiments in the 
L6 skeletal muscle and HepG2 human hepatoma cell lines evidencing that 
overexpression of Prep1 induces resistance to insulin action. However, whether 
and how Prep1-induced insulin-resistance affects triglycerides synthesis in 
liver is still unknown but important to clarify.  
In the present work, I show that in Prep1 hypomorphic mice serum level of 
triglycerides are strongly reduced, confirming our previous data about the 
reduction of hepatic TG content (Oriente et al. 2011). Thus, I focused my 
attention on the pathways inducing lipid synthesis. De novo lipogenesis plays a 
key role in hepatic lipid metabolism and is modulated by FAS, an enzyme that 
catalyzes the generation of palmitate from acetyl-CoA. In Prep1-deficient 
mice, FAS expression is significantly reduced, so I studied the activation of 
AMPK, which plays a key role in regulating carbohydrate and fat metabolism, 
serving as a metabolic master switch in response to alterations in cellular 
energy charge. In fact, AMPK turns off anabolic pathways and promotes 
catabolism by downregulating the activity of key enzymes of intermediary 
metabolism, such as ACC and FAS. Thus, AMPK cascades have emerged as 
novel targets for the treatment of obesity and fatty liver. My results show that 
the phosphorylation of AMPK is increased significantly in the liver of Prep1 
hypomorphic mice, but no differences are observed in AMPK total protein 
levels. It is known that activation of AMPK stimulates fatty acid oxidation and 
is accompanied by suppression of ACC activity, the enzyme that catalyzes 
malonyl CoA synthesis. The phosphorylation of ACC leads to an inactivation 
of the enzyme that, in turn, inhibits the other lipogenic enzymes of the 
pathway. Increasing evidence suggests that AMPK regulates ACC trough a 
49 
 
short-term regulation in which AMPK phosphorylates and inactivates ACC 
inhibiting TG synthesis, or trough a long-term mechanism. In the long-term, 
AMPK regulates hepatic lipogenic gene expression by inhibiting transcription 
factors, such as SREBP-1c and ChREBP, that directly regulate ACC gene 
transcription. Analysis of ACC activation and expression in Prep1i/+ mice 
revealed increased phosphorylation of the enzyme; but no change in ACC 
protein and mRNA expression suggesting that Prep1 controls ACC trough a 
short-term mechanism. 
AMPK is physiologically activated by the phosphorylation of threonine 172 
within the α subunit catalyzed by the kinase LKB1, the upstream kinase of 
AMPK. Neverthless, other proteins can activate AMPK, like for example 
CAMK2. Thus, I evaluated the role of these two kinases in Prep1i/+ mice and 
my results indicate that LKB1, but not CAMK2, controls AMPK activity. In 
fact, Prep1i/+ mice exhibit a very significant increase of LKB1 phosphorylation, 
while at variance, the phosphorylation of CAMK2 does not change. These 
results let me focus on the regulation of LKB1. This protein is phosphorylated 
at Ser428 by some kinases, such as PKCζ. In fact, phosphorylation of LKB1 at 
Ser428 induces nuclear export into the cytosol and its association with AMPK. 
Other kinases such as PKA are reported to phosphorylate LKB1-Ser428. 
Interestingly, analysis of the two kinases in Prep1i/+ mice reveals significant 
increased PKCζ phosphorylation, while PKA phosphorylation is unaffected in 
liver tissue from Prep1-deficient mice. These data demonstrate that, in Prep1-
deficient mice, the PKCζ-mediated  phosphorylation of LKB1 is important for 
the AMPK activation and inhibition of the TG synthesis.  
To further address my hypothesis, I have transfected human hepatocarcinoma 
cell lines (HepG2 cells) with Prep1. At variance with the liver of Prep1-
deficient mice, the overexpression of Prep1 significantly increases cellular lipid 
accumulation and FAS expression and induces a inhibition of ACC, AMPK, 
LKB1 and PKCζ phosphorylation.  
Our previous work showed that regulation of the tyrosine phosphatase SHP1 
gene function represents a relevant mechanism for the Prep1 control on insulin 
signaling and action in hepatocyte. The activation of the insulin receptor leads 
to the tyrosine phosphorylation of the insulin receptor substrate (IRS) proteins, 
that activates phosphatidylinositol 3-kinase (PI3K) and induces activation of 
downstream signaling molecules such as Akt/protein kinase B (Akt/PKB) and 
atypical protein kinase C-ζ (PKCζ). To better understand the functional 
relevance of Prep1 control on SHP1 expression to hepatic lipogenesis, I stably 
transfected HepG2 cells with Prep1 and a specific antisense silencing SHP1 
was added to these cells. Depletion of SHP1 partially rescued lipogenesis 
inhibition, thus establishing SHP1 as possible target of Prep1 in the liver. Other 
tyrosine phosphatases, such as PTP1B, have received particular attention in 
negative regulating of insulin signal transduction and is associated with the 
development of insulin-resistance. Moreover, at least one genetic 
polymorphism of PTP1B is associated with several features of the insulin-
resistance/metabolic syndrome (Di Paola et al. 2002). In my studies I have 
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excluded PTP1B because previously we have shown that its levels were 
unaffected both in liver tissue from Prep1-deficient mice and in cells 
overexpressing Prep1 (Oriente et al. 2011). However, given that SHP1 only 
partially contribute on Prep1-mediated TG synthesis, I supposed that other 
protein phosphatases might be involved in this mechanism. It is known that 
SH2-containing inositol 5′ phosphatase-2 (SHIP2) has been shown to have 
negative role on insulin signaling. Moreover, the molecular mechanism 
underlying insulin resistance in animal models of type 2 diabetes is involved, at 
least in part, at the step between PI 3-kinase and its downstream molecules, 
Akt and PKCζ. Thus, I hypothesized that there could be a possible involvement 
of SHIP2 in insulin-resistance and increased hepatic lipogensis. Interestingly, 
the levels of SHIP2 lipid phosphatases significantly decreases in Prep1 
hypomorphic mouse liver while undergoes opposite changes in cultured liver 
cells transiently transfected with a Prep1 cDNA. To specifically investigate the 
role of SHIP2, HepG2 cells stably overexpressing Prep1 were transfected with 
a phosphorothioate oligonucleotide antisense (SHIP2-AS) and a strongly 
inhibition of Prep1-mediated increase of TG synthesis was observed. Thus, 
regulation of the SHIP2 gene function seemed to represent a mechanism 
relevant to Prep1 control on hepatic lipid metabolism. SHIP2 downregulation 
in liver tissue from the Prep1-hypomorphic mice occurred both at the protein 
and at the mRNA levels, raising the possibility that Prep1 acts, at least in part, 
by regulating SHIP2 gene expression. Understanding how Prep1 might regulate 
the expression of SHIP2 gene is a critical point to better define the action of 
this transcription factor in modulating lipogenesis in liver. Thus, analyzing the 
4,000 base-pair region upstream SHIP2 transcription initiation site, I have 
identified that the regulatory region of SHIP2 gene contains two Prep1/Pbx1 
binding sites. The effects of Prep1 on gene regulation is tightly dependent on 
many interactors, which can recruit it in different transcription networks and 
modulate the target of its transcription activity. Thus, before studying the 
Prep1-mediated SHIP2 expression, I focused my attention on the role of Pbx1. 
In HepG2 cells Pbx1 mimics Prep1 action on cellular lipid accumulation, 
increasing FAS expression, ACC activity and inhibiting AMPK, LKB1, PKCζ-
mediated lipogenesis regulation. The association of Prep1 with Pbx1 is 
important to increase triglycerides synthesis, because using a Prep1HR1 mutant, 
this effect is lost. The Prep1HR1 mutant mutant contains one point mutation in 
the domain HR1 which is fundamental for the interaction between Prep1 and 
Pbx1, resulting in an abolishment of the recruitment and function of the 
transcription complex.  
Pbx proteins complexed with Prep1 exhibit strong affinity and specificity for 
different binding sites, the TGACAG sequence of the urokinase enhancer, the 
Pbx responsive sequence (PRS, TGATTGAT) and the b1-ARE R3 site 
(GTGATGGAT), a typical binding site restricted to a limit set of Hox proteins, 
including HOXB1 (Berthelsen et al. 1998). The DNA-target specificity of the 
Prep1/Pbx1 complex is restricted to the binding site sequence; my 
bioinformatic analysis of SHIP2 regulatory region indicates that Prep1 or a 
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preassembled Prep1–Pbx complex can functionally interact with specific 
SHIP2 sequences, by forming a transcriptionally active complex. In addition, 
ChIP and Re-ChIP assays with Prep1 and Pbx1 antibodies show that both 
transcription factors bind the SHIP2 regulatory region, suggesting that SHIP2 
gene is a target of the Prep1/Pbx1 complex. However, since Pbx1 increases the 
nuclear localization of Prep1 (Berthelsen et al. 1999; Jaw et al. 2000), it is also 
possible that the expression of Pbx1 causes the nuclear accumulation of Prep1, 
thereby enhancing its transcriptional effect on SHIP2. 
Data obtained about the role of Prep1/Pbx1 complex on SHIP2 are very 
interesting given that the phenotype of Prep1-hypomorphic mice could be in 
part related to that of SHIP2-null mice. Deficiency of  Prep1 and SHIP2 induce 
several perturbations of the wild-type phenotype. First, both Prep1-
hypomorphic and SHIP2-null mice were smaller than wild-type littermates. 
Second, SHIP2−/+ mice show insulin hypersensitivity with enhanced GLUT4 
translocation to the cell surface in response to low dose insulin, a similar 
phenotype observed in the muscle of Prep1-hypomorphic mice. Moreover, an 
examination of serum chemistry shows that serum triglycerides are 
significantly lower in Prep1-hypomorphic and SHIP2-null mice. Thus, both 
animal models perform increased insulin sensitivity and reduced TG levels. 
The excessive accumulation of triglycerides and the formation of hepatic lipid 
droplets may cause liver steatosis and progress to NASH in the long term. Next 
experiment will try to clarify the role of Prep1 and SHIP2 on the pathogenesis 
of NASH. 
In summary, the major finding of the present study is that Prep1-mediated 
SHIP2 expression induces an increase of TG synthesis by blocking PKCζ, 
LKB1, AMPK and ACC phosphorylation. Although the precise molecular 
mechanisms and signaling pathways regulated by Prep1 remain to be better 
clarified, suppression of this transcription factor may represent a beneficial 
strategy in the treatment of obesity and thereby prevent type 2 diabetes. Further 
focus on the pathways downstream of Prep1 may help to understand insulin-
mediated alterations in metabolism and lipogenesis. Nevertheless, my data 
have been obtained in murine models, thus another point which I would like to 
study in the future is the clinical relevance of Prep1 in humans. We have 
preliminary data showing that first-degree relatives of type 2 diabetics (these 
individuals have an high risk of type 2 diabetes) overexpress Prep1 compared 
to control individuals with no family history of diabetes. In addition, in these 
first-degree relatives, Prep1 expression levels negatively correlate with insulin 
sensitivity. These subjects have a very high risk of diabetes and are known to 
be insulin-resistant, suggesting that Prep1 overexpression may provide an early 
contribution to diabetes progression in these individuals. However, whether 
Prep1 overexpression induces insulin-resistance in human and whether it is 
sufficient to impair glucose tolerance is still unknown and will be the subject of 
my future studies. 
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6. CONCLUSIONS 
 
The liver is an insulin sensitive organ that plays a key role in the regulation of 
whole body energy homeostasis. Defective insulin signaling and development 
of insulin-resistance in the liver may have major consequences on energy 
balance and metabolism. 
In the present work I have focused my attention on Prep1 action on hepatic 
lipid metabolism. I have described that Prep1 deficiency in animal models 
decreases triglyceride synthesis in liver enhancing PKCζ, LKB1, AMPK and 
ACC phosphorylation. These effects are paralleled by a significant reduction of 
expression of SHP1 tyrosine phosphatase and SHIP2 lipid phosphatase. In 
particular, cellular models evidence that SHIP2 is a main target of Prep1 in the 
control of hepatic lipogenesis. This evidence let me focus my research activity 
on the transcriptional regulation of SHIP2 by the Prep1-Pbx1 complex. In this 
context, I have shown that Prep1-Pbx1 bind SHIP2 gene on two regulatory 
sequences upstream the ATG codon. 
In conclusion, these findings have contributed to underline the link between the 
TALE proteins, insulin-resistance and triglyceride synthesis and, in part, to 
clarify the role of tyrosine and lipid phosphatases on hepatic regulation of lipid 
metabolism. 
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Prep1 Controls Insulin Glucoregulatory Function in Liver
by Transcriptional Targeting of SHP1 Tyrosine
Phosphatase
Francesco Oriente,1 Salvatore Iovino,1 Serena Cabaro,1 Angela Cassese,1 Elena Longobardi,2,3
Claudia Miele,1 Paola Ungaro,1 Pietro Formisano,1 Francesco Blasi,2,3 and Francesco Beguinot1
OBJECTIVE—We investigated the function of the Prep1 gene in
insulin-dependent glucose homeostasis in liver.
RESEARCH DESIGN AND METHODS—Prep1 action on in-
sulin glucoregulatory function has been analyzed in liver of
Prep1-hypomorphic mice (Prep1i/i), which express 2–3% of
Prep1 mRNA.
RESULTS—Based on euglycemic hyperinsulinemic clamp stud-
ies and measurement of glycogen content, livers from Prep1i/i
mice feature increased sensitivity to insulin. Tyrosine phosphor-
ylation of both insulin receptor (IR) and insulin receptor sub-
strate (IRS)1/2 was significantly enhanced in Prep1i/i livers
accompanied by a specific downregulation of the SYP and SHP1
tyrosine phosphatases. Prep1 overexpression in HepG2 liver
cells upregulated SYP and SHP1 and inhibited insulin-induced IR
and IRS1/2 phosphorylation and was accompanied by reduced
glycogen content. Consistently, overexpression of the Prep1
partner Pbx1, but not of p160MBP, mimicked Prep1 effects on
tyrosine phosphorylations, glycogen content, and on SYP and
SHP1 expression. In Prep1 overexpressing cells, antisense silenc-
ing of SHP1, but not that of SYP, rescued insulin-dependent IR
phosphorylation and glycogen accumulation. Both Prep1 and
Pbx1 bind SHP1 promoter at a site located between nucleotides
!2,113 and !1,778. This fragment features enhancer activity and
induces luciferase function by 7-, 6-, and 30-fold, respectively, in
response to Prep1, Pbx1, or both.
CONCLUSIONS—SHP1, a known silencer of insulin signal, is a
transcriptional target of Prep1. In liver, transcriptional activation
of SHP1 gene by Prep1 attenuates insulin signal transduction and
reduces glucose storage. Diabetes 60:138–147, 2011
Prep1 is an homeodomain transcription factor ofthe three-amino acid loop extension (TALE) su-perclass of proteins (1) that dimerizes with Pbx1,enhancing target specificity and modulating tran-
scription regulatory function (2–8). Prep1 is essential for
embryonic development. Indeed, Prep1 null embryos die
before gastrulation (L.C. Fernandez-Diaz and F.B., unpub-
lished observations), whereas Prep1- hypomorphic mu-
tant mouse (Prep1i/i) embryos, which express 2 to 3% of
Prep1 mRNA and up to 10% of the protein, show a leaky
embryonic-lethal phenotype and defects in angiogenesis,
hematopoiesis, and eye development. Part of the Prep1i/i
phenotype depends on reduction of the Pbx protein level
(9–11).
In addition to Pbx, Prep1 also interacts with p160MBP in
competition with Pbx (12), preventing its proteosomal
degradation and enhancing its regulatory effect on PGC-1"
and hence on its regulation on glucose metabolism (13).
The few surviving Prep1i/i and the heterozygous Prep1i/#
mice show decreased insulin and glucagon production,
prolonged insulin response, and protection from insulin-
deficient diabetes. This phenotype is due to a complex
tissue-specific mechanism. At the skeletal muscle level,
the enhanced insulin sensitivity was due to a decrease in
p160MBP, resulting in activation of PGC-1", overexpres-
sion of GLUT4, and increased glucose uptake (13). On the
other hand, the level of Pbx1 was not changed, which
drastically increases the Pbx/p160 ratio. Different mecha-
nism must operate in liver since Pbx1 and p160MBP are
expressed at different levels compared with skeletal
muscle.
Liver gluconeogenesis depends on the enzymes G6Pase
and PEPCK, the expression of which requires PGC-1" as
well as other transcription factors, including Foxo1 (14–
17). For example, in liver, glucagon induces G6Pase and
PEPCK and activates gluconeogenesis via PGC-1" (14).
This agrees with the Prep1i/i phenotype that includes
smaller pancreas and reduced glucagon-circulating levels
(13). Whether and how Prep1 affects glucose metabolism
in liver is unknown at the present, but must be clarified to
elucidate how Prep1 regulates insulin-dependent glucose
metabolism at the whole-body level. Indeed, PGC-1" up-
regulation in Prep1-deficient mice is expected to produce
sustained gluconeogenesis. In contrast, these animals fea-
ture normal glucose tolerance and protection from
diabetes.
In liver, insulin-dependent glucoregulatory function is
controlled by a number of different mechanisms. Among
these, the function of several protein tyrosine phospha-
tases has been reported to play a major role. PTP1B, SYP,
and SHP1, for example, are known to negatively modulate
insulin action on liver glucose metabolism through ty-
rosine dephosphorylation of the insulin receptor and/or
IRS (18–20). At variance, the ubiquitously expressed cyto-
solic SHP2 phosphatase was described to positively mod-
ulate insulin signaling (21,22). Thus, the balance of these
individual phosphatases represents an important determi-
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nant of normal liver glucoregulation. How this balance is
maintained at the physiologic and molecular levels has
been only partially elucidated.
In the present work, we have focused on Prep1 action
on hepatic glucose metabolism. We show that in liver,
Prep1 restrains insulin action by activating transcription of
the SHP1 tyrosine phosphatase gene and inhibiting insulin
receptor and IRS signaling.
RESEARCH DESIGN AND METHODS
Materials. Media, sera, antibiotics for cell culture, and the lipofectamine
reagent were from Invitrogen (Grand Island, NY). The anti-Prep1 polyclonal
antibody and pBOS-Prep1, pSG5-Pbx1, PSG5-Prep1HR1, pRUFneo-p160 vec-
tors have been described previously (12,13). The PGC-1", actin, IR, Pbx1, Syp,
SHP1, PTP1B, G6Pase, and PEPCK antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA). The pY, IRS1, and IRS2 antibodies were from Upstate
Biotechnolgy (Lake Placid, NY). The p160 antibody was from Zymed Labora-
tories (San Francisco, CA). Protein electrophoresis reagents were from
Bio-Rad (Richmond, VA), Western blotting and enhanced chemiluminescence
(ECL) reagents from Amersham Biosciences (Arlington Heights, IL). All other
chemicals were from Sigma (St. Louis, MO).
Studies in mice. High-fat diet treatment of C57BL/6J mice was performed as
described by Vigliotta et al. (23). Prep1-targeted mice were generated by gene
trapping (Lexikon Genetics, The Woodlands, TX). Their general phenotype
has been previously described (10,11). Weight of Prep1i/# mice was slightly
lower than that of their nonhypomorphic littermates (13). All animal handling
conformed to regulations of the Ethics Committee on Animal Use of H.S.
Raffaele (Institutional Animal Care and Use Committee, permission number
207). Genotyping strategy has been previously described (13).
Hepatic tissue samples were collected rapidly after mice were killed with
a pentobarbitone overdose. Tissues were snap frozen in liquid nitrogen and
stored at!80°C for subsequent Western blotting as previously described (13).
Cell culture procedures and transfection. The HepG2 hepatocarcinoma
cells and NMuLi mouse liver cells were cultured at 37°C in Dulbecco’ s
modified Eagle’ s medium (DMEM) supplemented with 10% FCS, 2% L-
glutamine, 10,000 units/ml penicillin, and 10,000 $g/ml streptomycin. Tran-
sient transfection of Prep1, Prep1HR1, p160 and Pbx1 plasmids or Syp (5%-
CTCCGCGATGTCATGTTCCT-3%) and SHP1 (5%- GAGGTCTCGGTGAAAC
CACCT CACCATCCT-3%) phosphorothioate antisense oligonucleotides or
scrambled control oligonucleotides Syp (5%- TCGCCACGTCGCTCATTGTT-3%)
and SHP1 (5%-GTAGAGTTCCGTGAGACACCTCTCCACCAC-3%) were per-
formed by the Lipofectamine method according to the manufacturer’s instruc-
tion. In stable transfection studies, individual G418-resistant clones were
selected by the limiting dilution technique (G418 effective dose, 0.8 mg/ml).
The expression of Prep1 by the individual clones was quantitated by Western
blotting. In both transient and stable transfection, the efficiency was consis-
tently between 65 and 75%.
Determination of glycogen content and triglycerides levels. Glycogen
was isolated from liver tissue or HepG2 cells homogenized in 0.1% SDS,
saturated with Na2SO4 for 30% at 37°C, followed by ethanol (EtOH) precipita-
tion. Glycogen content was determined as previously described (24,25).
The triglyceride content was extracted from frozen liver tissues and
determined as described previously (25).
Euglycemic-hyperinsulinemic clamps. Six-month-old male mice were cath-
eterized via the right internal jugular vein under isoflorane anesthesia. After
loss of pedal and corneal reflexes was assured, a catheter (platinum-cured
silicone tubing, 0.020 internal diameter & 0.037 outer diameter; Harvard
Apparatus, Holliston, MA) was inserted into the right internal jugular and
advanced to the level of the superior vena cava. The catheter was filled with
saline, tunneled, and left in a subcutaneous pocket at the back of the neck. A
6-0 silk suture was attached to the free end of the catheter and exteriorized in
such a fashion as to allow retrieval of the catheter on the day of the
experiment. Mice were allowed to recover on a heating pad. After 5 days of
recovery, mice were subjected to clamp studies. The infusion studies lasted a
total of 90 min. At t ' 0 min, mice began receiving a constant infusion of
HPLC-purified [3H]glucose (0.1 $Ci/min; Perkin-Elemer), and insulin (3.5
mU/min/kg body weight; Humulin, Eli Lilly). A solution of glucose (20%) was
infused at a variable rate as required to maintain euglycemia (140–150 mg/dl).
Thereafter, plasma samples were collected to determine glucose levels (at t '
0, 30, 50, 60, 70, 80, and 90 min) as well as [3H]glucose specific activity (at t '
0, 30, 50, 60, 70, 80, and 90 min). Plasma glucose was measured by the glucose
oxidase method (Glucose Analyzer, Analox GM-7 microstat).
Under steady-state conditions for plasma glucose concentration, the Rd
equals the rate of glucose appearance (Ra). Ra was determined from the ratio
of the infusion rate for [3H]glucose (dpm) and the specific activity of plasma
[3H]glucose (dpm) under steady-state conditions. The rate of glucose produc-
tion was therefore obtained from the difference between Ra and the rate of
glucose infusion.
Western blot analysis and immunoprecipitation procedures. Tissue
samples were homogenized in a Polytron (Brinkman Instruments, NY) in 20 ml
Tissue Protein Extraction Reagent /g of tissue according to the manufacturer’s
instructions (Pierce, IL). Immunoprecipitation and Western blot analysis have
been performed as previously described (26).
Real-time RT-PCR analysis. Total cellular RNA was isolated from liver
tissue and HepG2 cells by using the RNeasy kit (QIAGEN Sciences, Germany),
according to the manufacturer ‘s instructions. We reverse-transcribed 1 $g of
tissue or cell RNA using Superscript II Reverse Transcriptase (Invitrogen, CA).
PCR reactions were analyzed using SYBR Green mix (Invitrogen, CA).
Reactions were performed using Platinum SYBR Green qPCR Super-UDG
using an iCycler IQ multicolor Real Time PCR Detection System (Biorad, CA).
All reactions were performed in triplicate and (-actin was used as an internal
standard. Primer sequences used were as follows. G6Pase R 5%-GTACCTCAG
GAAGCTGCCA-3%, G6Pase F: 5%-TTTGCTATTTTACGTAAATCACCCT-3%, PEPCK
R 5%-AATGTCATC ACCCACACA TTC- 3%, PEPCK F: 5%-ATG TATGTCATC CCA
TTC AGC- 3%,PGC-1" R 5%-AGGGTCATCGTTTGTGGTCAG-3%, PGC-1" F
5%CAGCGGTCTTAGCAC TCA G-3%, hSyp R 5%-GCTCTCAAAAGCCCTGTGTC-3%,
hSyp F 5% GCTGGGACAAGCTGAAAGTC-3%, hSHP1 R 5%-GTCTCCAAACCAC
CCACTGT-3%, hSHP1 F 5%-GACGTTTCTTGTGCGTGAGA-3%, hPTP1B R5%-
GCTCTCAAAAGCCCTGTGTC-3%, hPTP1B F 5%-GCTGGGACAAGCTGAAAGTC-
3%, mSyp R 5%-TGCCCAGCGTCTCCACCATG-3%, mSyp F 5%-AGCAACGA
CGGCAAGTCCAAAG-3%, mSHP1 R 5% TCCTCCGACTCCTGCTTCTTG 3%, mSHP1
F 5% GACCTGGTGGAGCACTTCAAG 3%, mPTP1B R 5% CTCTATGCAACCCAAG
GAACTG 3%, mPTP1B F 5% CTTCAGGTGGTGGAGACAGG 3%, (-actin F 5%-
GCGTGACATCAAAGAGAAG-3% and (-actin R 5%-ACTGTGTTGGCATAGAGG-3%.
Chromatin immunoprecipitation and luciferase assays. Chromatin im-
munoprecipitation (ChIP) and Re-ChIP assays were performed using nMuLi
cells as previously described (27). For luciferase assays, the mouse SHP1
fragment !1,887/#335 (region n. 2) was amplified by PCR from genomic
mouse DNA isolated from the murine liver cell line (NmuLi cells). The
following primers were used: F: 5%-KpnI- TCGGTGTGAGATCGGTACAA-3%
and R:5%-SacI- TCCGAGTTGGTGTCTCAGTG-3% (SHP1 n°2), (where SacI and
KpnI indicate the restriction sites added to the sequence). The amplified
fragments were cloned in the Plg3 promoter vector (Promega) by SacI and
KpnI. HeLa cells were cotransfected with 2 $g of SHP1 n°2 promoter vector
together with different amounts of Prep1 and Pbx1 expression vectors. Total
DNA content (up to 4 $g/plate) was normalized to the empty vector devoid of
Prep1 and Pbx1 coding sequence. Forty-eight hours after transfection, the
cells were harvested and lysed as described previously (27). Luciferase
activity was measured by a commercial luciferase assay kit (Promega). Values
were normalized for (-galactosidase. Statistical significance was evaluated by
t test analysis.
Statistical procedures. Data were analyzed with Statview software (Abacus
Concepts, Piscataway, NJ) by one-factor ANOVA. P values ) 0.05 were
considered statistically significant (23).
RESULTS
Hepatic glucose metabolism in Prep1-deficient mice.
To address the significance of Prep1 to the insulin-resis-
tant and diabetic liver, we first examined its expression in
high-fat diet-treated (HFD) and in diabetic db/db mice.
Hepatic expression of Prep1 was 37 and 67% higher,
respectively, in the HFD and db/db compared with the
control mice (Fig. 1A), suggesting a role of Prep1 in the
altered liver glucose metabolism and glucoregolatory func-
tion in the murine models. To investigate this issue in
greater detail, we compared liver glycogen and triglyceride
content in Prep1 hypomorphic mice (Prep1i/#; Prep1i/i)
and in their nonhypomorphic littermates (wild type). Gly-
cogen content was significantly increased in the hypomor-
phic mice and a Prep1 gene dosage effect was evidenced
(Fig. 1B; increases were twofold and threefold, respec-
tively, in the Prep1i/# and the Prep1i/i mice). At variance,
liver triglyceride content was reduced in the Prep1-defi-
cient mice (3.3 * 1.7 and 14 mg/g * 2.5 tissue, respec-
tively, in the Prep1i/# and the nonhypomorphic mice) (Fig.
1C). However, no significant difference was detected in
liver weight between Prep1 hypomorphic and wild-type
F. ORIENTE AND ASSOCIATES
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(WT) animals (data not shown). Expression of the major
gluconeogenic enzymes G6Pase and PEPCK was, respec-
tively, 45 and 30% reduced in these mice compared with
controls, both at the mRNA and the protein levels (Fig. 1D;
P) 0.01). We then measured liver sensitivity to insulin and
assessed glucose production by euglycemic hyperinsuline-
mic clamp in conscious Prep1 hypomorphic mice. In these
studies, the rate of insulin infusion was selected to gener-
ate a physiologic increase in plasma insulin (to 8 ng/ml) to
submaximally stimulate glucose uptake and inhibit glu-
cose production (28). As shown in Fig. 1E, basal glucose
production (mainly gluconeogenic after 16-h starvation)
was slightly but significantly lower in the hypomorphic
mice. Insulin suppressed hepatic glucose production to
lower levels in Prep1i/# mice (8 * 2.2 mg/kg/min) com-
pared with WT (15 * 3.1 mg/kg/min), reflecting enhanced
hepatic sensitivity to insulin. The increased hepatic sensi-
tivity to insulin in the hypomorphyc mice was further
supported by the higher glucose infusion rate (GIR) re-
quired to maintain euglycemia during the clamp (60 * 6
mg/kg/min in the Prep1i/# vs. 40 mg/kg/min* 6 in the WT)
(Fig. 1F).
The increased insulin sensitivity in muscle from Prep1
hypomorphic mice is largely contributed by reduced p160
stability, followed by higher PGC-1" levels in this tissue
(13). At variance with muscle, p160 abundance was very
low in liver and did not change in Prep1 hypomorphic
mice (Fig. 2A). PGC-1" levels also showed no change in
hypomorphic liver (Fig. 2B), suggesting that the action of
Prep1 on insulin sensitivity may involve different mecha-
nisms in liver and skeletal muscle. Also, at variance with
muscle (13), Pbx1 was abundantly expressed in liver from
WT mice but extremely reduced in those from their
Prep1-deficient littermates (Fig. 2C).
Prep1 effect on the insulin signaling pathway in
mouse liver. To further analyze Prep1 action on liver
sensitivity to insulin, we first profiled the initial steps of
the insulin-signaling cascade, both at the intracellular
abundance and at the activation levels. No change was
evidenced in either insulin receptor, IRS1 or IRS2 protein
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FIG. 1. Hepatic phenotype in HFD, db/db and in Prep1i/! mice. A: Livers from WT, HFD, db/!, and db/db mice were dissected, solubilized, and
Western blotted with anti-Prep1 antibodies. Blots were revealed by ECL and autoradiography and bands quantitated by laser densitometry and
normalized for actin. Each bar represents the mean " SD of duplicate determinations in seven mice per group. B: Prep1 hypomorphic and their
nonhypomorphic littermates (WT) were injected with insulin intraperitoneally (0.75 mU/g body weight). After 2 h, livers were isolated and
glycogen content was measured as described in RESEARCH DESIGN AND METHODS. Bars represent the means " SD of determinations in 12 mice per
group. C: Intrahepatic triglyceride content was measured as described in RESEARCH DESIGN AND METHODS. Bars represent the means " SD of
determinations in nine mice per group. D: G6Pase and PEPCK mRNA and protein content was determined by real-time RT-PCR analysis of total
RNA isolated from liver of Prep1i/! and control mice injected with insulin for 1 h, using #-actin as internal control. Bars represent the mean "
SD of four independent experiments, in each of which reactions were performed in triplicate using the pooled total RNAs obtained from six mice
per genotype. Glucose production (E) and glucose infusion rate (F) were assessed by euglycemic hyperinsulinemic clamp. All measurements were
performed during the final 40 min of the 90-min clamp procedure, after steady-state conditions for plasma glucose and insulin concentrations,
glucose specific activity, and rates of glucose infusion were achieved as described in RESEARCH DESIGN AND METHODS. Asterisks denote statistically
significant differences (*P < 0.05; **P < 0.01; ***P < 0.001).
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levels (Fig. 3A). However, tyrosine phosphorylation of all
of these proteins was significantly and gene dosage-depen-
dently increased in the hypomorphic mice. These changes
were accompanied by no change in the amount as well as
the phosphorylation of known negative regulators of the
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FIG. 3. Insulin signaling in liver of Prep1-hypomorphic mice. A: Protein
lysates (250 $g) from liver of WT and Prep1-hypomorphic mice were
immunoprecipitated with IR, IRS1 or IRS2 antibodies followed by
blotting with pY, IR, IRS1, or IRS2 antibodies. Actin antibodies were
used for the normalization. B: SYP, PTP1B, and SHP1 protein abun-
dance was measured by Western blot on hepatic tissues from hypomor-
phic and control mice using specific antibodies. Actin antibodies were
used for the normalization. All blots were revealed by ECL and
subjected to autoradiography. The autoradiographs shown are repre-
sentative of three (A) and four (B) independent experiments. Each bar
in panel B represents the mean " SD of duplicate determinations in 10
mice per group. C: The abundance of the indicated mRNA was deter-
mined by real-time RT-PCR analysis of total RNA isolated from the
liver of hypomorphic and control mice, using #-actin as internal
standard. Bar represents the mean " SD of four independent experi-
ments, in each of which reactions were performed in triplicate using
the pooled total RNAs obtained from six mice per genotype. Asterisks
denote statistically significant differences (*P < 0.05; **P < 0.01;
***P < 0.001).
A α-p160
α-actin
0
25
50
75
100
125
150
175
* *
muscle
*
liver
Prep1i/iWT Prep1i/iWT
p1
60
 le
ve
ls
(A
rb
itr
ar
y 
un
its
)
α-PGC-1α
α-actin
0
25
50
75
100
Prep1i/+WT Prep1i/iH
ep
at
ic
 P
G
C-
1α
le
ve
ls
(A
rb
itr
ar
y 
un
its
)
α-Pbx1
α-actin
0
25
50
75
100
125
150
175 **
muscle liver
Prep1i/iWT Prep1i/iWT
Pb
x1
 le
ve
ls
(A
rb
itr
ar
y 
un
its
)
B
C
**
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four independent experiments. Bars represent the mean " SD of
duplicate determinations in 10 mice per group. Asterisks denote
statistically significant differences (*P < 0.05; **P < 0.01).
F. ORIENTE AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 141
insulin receptor kinase, including PKC" and -+, ERK1/2,
JNK, and GRB10 (data not shown). Interestingly, protein
levels of the tyrosine phosphatases SYP and SHP1 were
reduced, respectively, by threefold and twofold in the
Prep1i/i mouse livers (Fig. 3B; P ) 0.001) and more
moderately in the Prep1i/#mice. This reduction seemed at
least in part transcriptional as it was observed also at the
mRNA level and was specific for the two phosphatases
(Fig. 3C). Indeed, PTP1B tyrosine phosphatase levels
showed no difference in the hypomorphic mice and in their
nontransgenic littermates. Activation of the downstream
insulin pathway was also observed, with increased phos-
phorylation of both AKT and Foxo1 (data not shown).
Prep1 regulates insulin action in HepG2 cells. We
have transiently transfected a Prep1 cDNA in the HepG2
hepatoma cells. As shown in Fig. 4A, Prep1 overexpres-
sion almost completely prevented insulin-induced tyrosine
phosphorylation of the insulin receptor, IRS1 and IRS2. No
change was evidenced in the abundance of any of these
proteins. However, Prep1 transfection upregulated SYP
and SHP1 expression at both the mRNA and the protein
levels, but had no effect on PTP1B (Fig. 4B).
Prep1 transfection upregulated Pbx1 levels in the
HepG2 cells (Fig. 4A). Interestingly, transfection of the
Prep1HR1mutant cDNA, which is unable to bind Pbx1 (12),
had no effect on either the phosphorylation of insulin
receptor, IRS1 and IRS2 or the levels of SYP and SHP1
tyrosine phosphatase (Fig. 4B). This indicates that the
Prep1-Pbx1 dimer controls insulin action in liver cells.
Consistent with this hypothesis, overexpression of a
Pbx1 cDNA in HepG2 cells mimicked Prep1 effects on
insulin-stimulated tyrosine phosphorylation of the insulin
receptor and IRS-1/2 (Fig. 5A), as well as on the level of
SYP and SHP1 (Fig. 5B). At variance, liver cell overexpres-
sion of the other major Prep1 partner, p160, elicited no
effect on these early steps in the insulin signaling cascade
(Fig. 5C). Importantly, transfection of the Prep1 or Pbx1
cDNAs, but not that of the Prep1HR1 mutant, abolished
insulin-induced glycogen accumulation in the HepG2 cells
(Fig. 5D). The failure of Prep1HR1 to mimic Prep1 effects
indicated that Prep1 action is exerted via dimerization
with Pbx1 rather than via p160.
SHP1 mediates the effect of Prep1 on insulin signal-
ing. To explore the significance of SYP and SHP1 tyrosine
phosphatases to Prep1 regulation of insulin signaling in
liver, we have stable transfected a Prep1 full-length cDNA
in the HepG2 cells. Several clones were obtained, and
three of those, expressing increasing levels of Prep1, were
selected and further characterized (Fig. 6A). The
HepG2Prep1c clone overexpressed Prep1 by fivefold and
featured a fourfold and threefold increased cellular con-
tent of SYP and SHP1, respectively (Fig. 6B). SYP and
SHP1 levels in the HepG2Prep1a and HepG2Prep1b cells
directly paralleled the lower level of Prep1 overexpression
in each clone (data not shown). Transient transfection of
the HepG2Prep1c cells with phosphorothioate antisense
oligonucleotides specific for SYP (SYP-AS) caused a ,65%
reduction in SYP levels but elicited almost no change in
insulin-stimulated phosphorylation of the insulin receptor,
suggesting no change in insulin action in these cells (Fig.
6C). At variance, treatment with SHP1 antisense oligonu-
cleotides (SHP1-AS) silenced SHP1 by only 50% but in-
creased insulin receptor tyrosine phosphorylation by
almost threefold (Fig. 6D). Indeed, the impaired insulin-
dependent accumulation of glycogen observed in liver
cells overexpressing Prep1 was unaffected by SYP silenc-
ing but was rescued by the SHP1 AS (Fig. 6E). Thus, the
SHP1 gene mediates Prep1 control on insulin signaling in
the HepG2 hepatoma cells.
Prep1 regulation of SHP1 gene transcription. We
therefore examined the further possibility that Prep1
directly regulates SHP1 gene function. Bioinformatic anal-
ysis revealed the presence of several potential binding
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FIG. 4. Effect of the overexpression of Prep1 and Prep1HR1 mutant on
insulin signaling in HepG2 cells. A: HepG2 cells were transiently
transfected with the Prep1 and Prep1HR1 mutant and exposed to 100
nmol/l insulin for 5 min. Cells were then solubilized and lysates were
immunoprecipitated with anti IR, IRS1, or IRS2 antibodies followed by
blotting with pY, IR, and IRS1 or IRS2 antibodies. Actin antibodies
were used for normalization. Bands were revealed by ECL and autora-
diography. The autoradiograph shown is representative of five inde-
pendent experiments. B: Lysates from HepG2 cells overexpressing
Prep1 or the Prep1HR1 mutant were blotted with SYP, PTP1B, and
SHP1 antibodies, followed by ECL and densitometry. Each bar repre-
sents the mean " SD of duplicate determinations in four independent
experiments. The levels of SYP, PTP1B, and SHP1 mRNAs in cells
transfected with the Prep1 and Prep1HR1 mutant cDNAs was quanti-
tated by real-time RT-PCR analysis, using # actin as internal standard.
Bars represent the mean " SD of four independent experiments.
Asterisks denote statistically significant differences (**P < 0.01;
***P < 0.001).
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sites for both Prep1 and Pbx1 in the 4,000 base pair region
upstream the SHP1 transcription initiation site. By ChIP,
two of these sites bound Prep1 (Fig. 7A; positions nucle-
otide [nt] !2,489 to !2,139, nt !2,113 to !1,778), but
re-ChIP assays revealed that Pbx1 was simultaneously
present only at position nt !2,113 to !1,778. To investi-
gate whether this last region features enhancer activity,
we subsequently cloned this fragment in the pgl3 basic
construct upstream the luciferase gene (pgl3LUC). The
construct was then cotransfected in HeLa cells together
with the Prep1, Pbx1 cDNAs or both and luciferase
activity was measured (Fig. 7B). Prep1 and Pbx1 increased
the SHP1 reporter activity, respectively, by 7.1-fold and
6-fold. Simultaneous cotransfection of the two plasmids
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FIG. 5. Effect of Pbx1 and p160 overexpression on insulin signaling in HepG2 cells. HepG2 cells transiently overexpressing Pbx1 (A) or p160
(C) were treated with 100 nmol/l insulin for 5 min, lysed, immunoprecipitated with anti IR, IRS1, or IRS2 antibodies, and analyzed by
Western blot with pY, IR, IRS1, or IRS2 antibodies. Identical aliquots of the lysates were also blotted with Pbx1 (A) or p160 (C) or actin
antibodies (A and C). Bands were revealed by ECL and autoradiography. The autoradiograph shown is representative of five independent
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caused an almost 30-fold induction, indicating SHP1 tran-
scriptional regulation by the Prep1/Pbx1 complex.
DISCUSSION
Previous studies have identified Prep1 as a physiologic
regulator of insulin-mediated glucose metabolism in skel-
etal muscle (13). In Prep1-deficient mice, muscle sensitiv-
ity to insulin action on glucose disposal is significantly
increased, due to downregulation of the major Prep1
partner p160 and induction of the GLUT4 gene activator
PGC-1 " (13). In the present paper, we show that in
high-fat diet-treated or db/db mice, hepatic Prep1 levels
are increased, suggesting a role of Prep1 in controlling
insulin sensitivity and glucose metabolism in this organ as
well. Indeed, Prep1-deficient mice showed increased he-
patic glycogen content and decreased glucose output and
triglyceride levels. Hypoinsulinemia, which represents a
prominent feature of the Prep1-deficient mice (13), is
likely essential to enable these animals to maintain plasma
glucose levels only slightly below those of their nonhypo-
morphyc littermates. The mechanisms responsible for
Prep1 action in liver differ from those in the skeletal
muscle, however. First, at variance with muscle, Prep1
major functional partner in liver appears to be Pbx1 rather
than p160. We have shown that in this organ, Prep1
expression determines Pbx1 levels as Prep1-hypomorphic
mice exhibit a very significant reduction of liver Pbx1.
Importantly, Pbx1 mimics Prep1 action on glycogen con-
α-Prep1
HepG2
HepG2Prep1A
HepG2Prep1B
HepG2Prep1C
A
C
D
HepG2Prep1CHepG2
α-SYP
α-SHP1
α-actin
B
α-SYP
α-actin
- +        - +     insulin
E
I.P.α-IR
W.B. α-pY
I.P.α-IR
W.B. α-IR
0
20
40
60
80
100
- + insulin
G
ly
co
ge
n 
C
on
te
nt
( µ
g/
m
g 
pr
ot
ei
n)
- + - + - +
SYP
SC
SYP
AS
SHP1
SC
SHP1
AS
SYP SC SYP AS
**
- +        - +     insulin
SHP1 SC SHP1 AS
α-SHP1
α-actin
I.P.α-IR
W.B. α-pY
I.P.α-IR
W.B. α-IR
FIG. 6. Effect of SYP and SHP1 antisense oligonucleotides on insulin signaling in HepG2 cells stable transfected with Prep1. A: HepG2 cells were
stable transfected with a Prep1 cDNA, as described under RESEARCH DESIGN AND METHODS. Clones of cells expressing varying levels of Prep1
(HepG2Prep1A, HepG2Prep1B, HepG2Prep1C) and the untransfected cells (HepG2) were analyzed by immunoblotting with Prep1 antibodies and
autoradiography. B: Lysates from HepG2or HepG2Prep1c cells were analyzed by immunoblotting with SYP, SHP1 or actin antibodies followed by
ECL and autoradiography. C and D: HepG2or HepG2Prep1c cells were transfected with SYP (SYP-AS) (C) or SHP1 (SHP1-AS) (D) specific
phosphorothioate antisense oligonucleotides, stimulated with 100 nmol/l insulin for 5 min and immunoprecipitated with insulin receptor
antibodies followed by blotting with either pY or IR antibodies. For control, identical aliquots of the lysates were also blotted with SYP, SHP1,
or actin antibodies. Bands were revealed by ECL and autoradiography as reported under RESEARCH DESIGN AND METHODS. The autoradiographs shown
are representative of four independent experiments. E: The HepG2Prep1c cells were transfected with SYP-AS and the SHP1-AS and further
stimulated with 100 nmol/l insulin for 5 min. Glycogen content was then assayed as described under RESEARCH DESIGN AND METHODS. Bars represent
mean values " SD of determinations in four independent experiments, each in duplicate. Asterisks denote statistically significant differences
(**P < 0.01).
PREP1 AND LIVER GLUCOREGULATORY FUNCTION
144 DIABETES, VOL. 60, JANUARY 2011 diabetes.diabetesjournals.org
tent in hepatocytes, whereas p160, which is expressed at
very low levels in this cell type and is not regulated by
Prep1, does not. Second, Prep1 does not induce repression
of PGC-1" levels in the liver cells. Indeed, the repression
of PGC-1" occurring in skeletal muscle is achieved by
Prep1 increase in p160 half-life which directly represses
PGC-1" (13). Foxo1 nuclear localization is a major event
determining PGC-1" induction of the key gluconeogenetic
genes G6Pase and PEPCK (17). In Prep1-hypomorphic
mice, Akt as well as Foxo1 phosphorylation is increased,
indicating induced nuclear export (data not shown). We
suggest that the reduced nuclear abundance of Foxo1
may, at least in part, explain how the upregulated insulin
signaling observed in Prep1i/i mice downregulates G6Pase
and PEPCK gene transcription in the presence of unal-
tered PGC-1" levels.
Analysis of the initial steps in insulin signaling in the
Prep1-deficient mouse liver revealed increased tyrosine
phosphorylation of both insulin receptor and the major
IRSs present in these cells. Interestingly, although no
change in the intracellular levels of these proteins was
detected, the levels of both the SYP and SHP1 tyrosine
phosphatases were found significantly decreased in Prep1-
hypomorphic mouse liver and underwent opposite
changes in cultured liver cells transiently transfected with
a Prep1 cDNA. Previously published data from gene
knockout and transgenic overexpression models have
identified an important role of phosphotyrosine phospha-
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tases in the regulation of insulin sensitivity and glucose
homeostasis in vivo (19,20,22). The PTP1B phosphoty-
rosine phosphatase has received particular attention as
genetic and biochemical findings indicate a key inhibitory
role for PTP1B in modulating insulin signaling (29,30).
However, PTP1B levels were unaffected both in liver
tissue from Prep1-deficient mice and in cells overexpress-
ing Prep1, indicating specificity in Prep1 control of phos-
photyrosine phosphatase. More recent studies in SHP1-
deficient mice have shown an important role for SHP1 in
the modulation of insulin sensitivity and glucose metabo-
lism at the whole-body as well as liver levels (31). In this
study, the functional relevance of Prep1 control of SHP1
versus SYP expression to hepatic sensitivity to insulin was
assessed in further experiments in HepG2 liver cells stable
transfected with Prep1. These cells feature a very signifi-
cant reduction of insulin effect on glycogen accumulation.
However, antisense silencing of SHP1, though not of SYP,
rescued insulin effect in these cells, thus establishing SHP1
as the functionally relevant target of Prep1 in the liver.
Previous in vitro and in vivo studies of SHP1 function have
identified the insulin receptor as the primary target of
SHP1 action in the upstream insulin signaling cascade
(31,32). Based on this information, we propose that en-
hanced insulin action in the liver of Prep1-deficient mice
results from reduced SHP1-insulin receptor binding and
attenuated dephosphorylation with secondary activation
of the IRS system.
SHP1 downregulation in liver tissue from the Prep1-
hypomorphic mice occurred both at the protein and at the
mRNA levels, raising the possibility that Prep1 acts, at
least in part, by regulating SHP1 gene expression. Indeed,
we show that the regulatory region of SHP1 gene contains
several Prep1 binding sites in the 4,000 base-pair region
upstream SHP1 transcription initiation site and one Prep1/
Pbx1 binding site responding to the ectopic expression of
Prep1 and Pbx1 in cotransfection experiments in vitro. In
these assays, a fragment containing single Prep1/Pbx1
binding site displays a powerful enhancer function. In
addition, ChIp experiments with Prep1 and Pbx1 antibod-
ies showed that these proteins bind the SHP1 regulatory
region, suggesting that SHP1 gene is a target of the
Prep1/Pbx1 complex and not just Prep1. However, since
Pbx1 increases the nuclear localization of Prep1 (7,8), it is
also possible that the forced expression of Pbx1 causes
the nuclear accumulation of Prep1, thereby enhancing its
transcriptional effect on SHP1.
At variance with the liver, in muscle cells, the prevalent
association of Prep1 with p160, rather than with Pbx1, may
account for the lack of significant SHP1 upregulation by
Prep1 (data not shown) and the reported lower abundance
of SHP1, particularly in the nuclear compartment of mus-
cle cells (33,34). Thus, at least in part, different partners
may account for the tissue specificity in Prep1 regulatory
functions. Variation in Prep1 action in the major insulin-
responsive tissues are likely relevant to the phenotype of
Prep1-hypomorphic and are paralleled by the phenotype
of SHP1-deficient mice. Both of these mice are markedly
glucose tolerant and insulin sensitive, at both muscle and
hepatic levels (31,13). In both mouse models, SHP1 down-
regulation causes improved insulin-dependent suppres-
sion of hepatic glucose output. However, the enhanced
peripheral (muscle) sensitivity to insulin in the SHP1-
deficient mice is further contributed by p160 repression in
the Prep1-hypomorphic mouse muscles (13).
In conclusion, we have identified the SHP1 tyrosine
phosphatase, a known negative regulator of insulin signal-
ing, as a novel transcriptional target of Prep1. In the liver,
Prep1 silencing enhances insulin signaling, thereby in-
creasing glucose storage and reducing glucose output.
This effect might be further amplified by the reduction in
glucagon levels which also occurs in Prep1 hypomorphic
mice (13). Indeed, these mice feature a slower recovery
from insulin-induced hypoglycemia when compared with
their nonhypomorphic littermates, and they appear to
continue to accumulate glycogen (13). The findings re-
ported in the present paper might have clinical relevance
as preliminary evidence in our laboratory indicates that
Prep1 gene is overexpressed in euglycemic offspring of
type 2 diabetic individuals. These subjects have a very high
risk of diabetes (35) and are known to be insulin resistant,
suggesting that Prep1 overexpression may provide an
early contribution to diabetes progression in these individ-
uals. Whether and how genetic variability at the Prep1
locus affects glucose tolerance in humans is an important
issue that deserves to be investigated in detail.
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ABSTRACT 
 
TGF-beta1 has been shown to induce autophagy in certain cells but whether and how this action is 
exerted in muscle and whether this activity relates to TGF-beta1 control of muscle cell 
differentiation remains unknown. Here we show that expression of the autophagy-promoting 
protein PED/PEA-15 progressively declines during L6 and C2C12 skeletal muscle cell 
differentiation. PED/PEA-15 underwent rapid induction upon TGF-beta1 exposure of L6 and 
C2C12 myoblasts, accompanied by impaired differentiation into mature myotubes. TGF-beta1 also 
induced autophagy in the L6 and C2C12 cells through a PP2A/FoxO1-mediated mechanism. Both 
the TGF-beta1 effect on differentiation and that on autophagy were blocked by specific PED/PEA-
15 ShRNAs. Myoblasts stably overexpressing PED/PEA-15 did not differentiate and showed 
markedly enhanced autophagy. In these same cells, the autophagy inhibitor 3-Methyladenine 
rescued TGF-beta1 effect on both autophagy and myogenesis, indicating that PED/PEA-15 
mediates TGF-beta1 effects in muscle. Muscles from transgenic mice overexpressing PED/PEA-15 
featured a significant number of atrophic fibers, accompanied by increased LC3II to LC3I ratio and 
reduced PP2A/FoxO1 phosphorylation. Interestingly these mice showed significantly impaired 
locomotor activity compared to their non-transgenic littermates. TGF-beta1 causes transcriptional 
upregulation of the autophagy-promoting gene PED/PEA-15, which in turn is capable to induce 
atrophic responses in skeletal muscle in vivo. 
 
3 
INTRODUCTION 
 
The superfamily of Transforming Growth Factor-beta (TGF-beta) cytokines are ubiquitously 
expressed and induce a wide variety of effects ultimately depending on the cell context and 
including regulation of cell growth, proliferation, differentiation, adhesion, migration and apoptosis 
(1-6). Also, different members of the TGF-beta superfamily, including the archetypal TGF-beta 
family member TGF-beta1,  have been found to inhibit myogenic differentiation in primary cultures 
and in myoblast cell lines from different species (7-9). These findings have evoked considerable 
translational interest, as inhibitors of the TGF-beta signalling cascade are currently being targetted 
to reduce muscle wasting accompanying both acute metabolic derangements and chronic disorders 
such as cancer, congestive heart failure, sarcopenia, acquired immunodeficiency and long-lasting 
and poorly compensated diabetes mellitus (10). 
 
In all of these catabolic conditions, protein breakdown is enhanced and exceeds protein synthesis, 
resulting in loss of muscle mass and myofiber atrophy. There is substantial evidence indicating that 
autophagic flux is increased during muscle atrophy due to up or down-regulation of different sets of 
genes designated atrogenes (11,12). These include genes encoding proteins that are degraded when 
autophagosomes fuse with lysosomes, such as the microtubule-associated protein 1 light chain 3 
(LC3I). The latter is converted to LC3II during autophagy, so that the LC3II to LC3I ratio is often 
taken as representative of autophagy induction. However, whether autophagy itself causes muscle 
fiber degeneration remains a debated issue (13).   
 
While TGF-beta1 has recently been shown to represent an important regulator of autophagy in liver 
and mammary cells (14), autophagy in the skeletal muscle is peculiar as compared to that occurring 
in other metabolically relevant tissues. During fasting, most tissues show a transient activation of 
autophagy. In contrast, skeletal muscle shows a persistent generation of autophagosomes that 
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continues for days (11), suggesting that different mechanisms control autophagosome formation 
during short or long periods of induced autophagy. Whether and how TGF-beta1 features 
autophagy promoting activity in muscle cells and whether this activity may lead to impaired 
myogenesis is unknown. 
 
Phosphoprotein Enriched in Diabetes/Phosphoprotein Enriched in Astrocytes (PED/PEA-15) is a 15 
KDa molecule which binds to different signalling proteins thereby regulating their function and 
several survival and metabolic transduction pathways (15,16). PED/PEA-15 cellular levels are 
controlled by both transcriptional and post-translational mechanisms (16) which have been shown 
to be dysregulated in human disorders including type 2 diabetes. Many type 2 diabetic individuals 
feature exagerated expression of PED/PEA-15 (17,18), leading to impaired insulin action and 
secretion and, possibly, contributing to diabetes long-term complications (19). Quite recently, 
evidence has been reported indicating that PED/PEA-15 promotes autophagy in glioma cells 
through a JNK-dependent mechanism (20), rendering the cells resistant to starvation and other 
adverse stimuli. In the present work, we show that PED/PEA-15 autophagy-promoting action is 
necessary for enabling complete TGF-beta1 control of myogenesis. 
 
 
RESULTS 
 
Effect of PED/PEA-15 on L6 cell differentiation - Low serum exposure causes L6 and C2C12 
skeletal muscle cells to spontaneously differentiate in culture with the generation of multinucleate 
myotubes (7-9, 21). As previously reported (7-9), the L6 and C2C12 myotube formation is 
accompanied by upregulation of a number of genes including MyoD1, myogenin and GLUT4. 
Unexpectedly however, these same gene profile studies revealed that expression of the autophagy 
regulator PED/PEA-15 underwent progressive reduction both during L6 and C2C12 cell 
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differentiation (Fig.1A, left panel). Similar changes occurred in the case of PED/PEA-15 protein 
levels (right panel), raising the possibility that this multifunctional molecule exerts a previously 
unidentified physiological role in myogenesis. To test this hypothesis further, we have transfected 
L6 or C2C12 myoblasts with a PED/PEA-15 cDNA, increasing PED/PEA-15 levels by 
approximately 10-fold (Fig.1B, top panel). We then compared differentiation in these cells and in 
cells transfected with the empty vector. As shown in Fig.1B,C, PED/PEA-15 overexpression 
impaired myotube formation both in L6 and C2C12 and reduced activation of the myogenesis 
markers MyoD1, myogenin and GLUT4 by > 2-fold in these cell types. At variance, the abundance 
of GLUT1 mRNA was 3-fold higher in PED/PEA-15-transfected as compared to the control cells. 
 
Role of PED/PEA-15 in TGF-beta1 action - To explore the role of PED/PEA-15 in muscle 
differentiation in greater detail, we have further examined its expression in L6 and C2C12 
myoblasts upon addition of TGF-beta1 into their culture medium. Indeed, TGF-beta1 exerts a 
physiological role in controlling muscle development and constrains myogenesis in different 
cultured skeletal muscle cells (7-9). Interestingly, TGF-beta1 exposure enhanced PED/PEA-15 
expression by almost 5-fold upon 6h exposure (Fig.2A) and exhibited a consistent time- and dose-
dependent effect on PED/PEA-15 protein levels as well (data not shown). The effect of TGF-beta1 
on PED/PEA-15 expression was significantly reduced in L6 (or C2C12, data not shown) cells  by 
the SB431542 inhibitor of the TGF-beta1 receptor, in parallel with SMAD3 phosphorylation 
(Figs.2B,C). Significant inhibition of TGF-beta1 effect was also achieved using a specific 
phosphorothioate antisense of SMAD3 (SMAD3 AS), indicating that TGF-beta1 stimulates 
PED/PEA-15 expression in a TGF-beta1R/SMAD3-dependent manner.  
Based on MyoD1, Myogenin and GLUT4 mRNA levels, TGF-beta1 treatment impaired L6 
myoblasts differentiation (Fig.3A-C). This effect was largely prevented by two specific ShRNAs 
(ShPED1 and ShPED2) which silence PED/PEA-15 expression by >70% (Fig.3A-D). The effect of 
TGF-beta1 on myotube generation was similarly affected by the PED/PEA-15 ShRNA  (Suppl. 
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Fig.1). Phosphorylation of PED/PEA-15 was also required for TGF-beta1-mediated myoblasts 
differentiation. In fact, in presence of  the PEDS116A mutant, TGF-beta1 failed to reduce MyoD1, 
Myogenin and GLUT4 mRNA levels (Fig.4A-D). Thus, in the L6 skeletal muscle cells, the 
complete regulatory role of TGF-beta1 on myogenesis requires the impact of TGF-beta1 signalling 
on PED/PEA-15. Same results were obtained in C2C12 (data not shown). 
 
Promotion of autophagy by TGF-beta1 in L6 cells - Current evidence indicates that fine tuning 
of autophagy plays a major role in enabling differentiation (11-13). This observation led us to 
hypothesize that the recently recognized autophagy-promoting function of PED/PEA-15 (20) is 
necessary for the myogenesis constrain imposed by TGF-beta1, as TGF-beta1 has also been very 
recently shown to induce autophagy in non-muscle cells (14). FACS analysis of acridine orange-
stained cells revealed that differentiating L6 (or C2C12, data not shown) cells treated with TGF-
beta1 for 6 days accumulated acidic vescicular organelles (AVOs, a prominent feature of 
autophagy) to a significantly greater extent than control cells (Fig.5A). In parallel, TGF-beta1 
treatment significantly increased both LC3I to LC3II conversion and Beclin 1 cell abundance, two 
known markers of autophagy activation (Fig.5B). In addition, exposure of L6 or C2C12 
differentiating cells to the autophagy inhibitor 3-Methyladenine led to rescue of the myotube 
differentiation markers in the presence of TGF-beta1 (Fig.5C), indicating that promotion of 
autophagy by TGF-beta1 is relevant to the differentiation constrain. Previous studies revealed that 
the forkhead transcription factor FoxO1 regulates the expression of several autophagy-related 
genes, including Beclin1 and LC3 and induces muscle wasting (22-25). Consistently, exposure of 
L6 or C2C12 differentiating cells to TGF-beta1 led to dephosphorylation of both FoxO1 and of its 
upstream regulator, the PP2A serine/threonine phosphatase (Fig.5D) 
 
PED/PEA-15 promotion of autophagy mediates TGF-beta1 effect on differentiation in L6 cells 
- The overexpression of PED/PEA-15 (10-fold above the endogenous levels) was sufficient to 
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determine a 10-fold increase in AVO accumulation, enhanced LC3I to LC3II conversion and 
augmentation in Beclin1 abundance (Fig.6A,B). As it is the case for myogenesis, ShPED1 (or 
ShPED2, data not shown) vector silencing of endogenous PED/PEA-15 impaired TGF-beta1 effects 
on both AVO accumulation and the autophagy markers (Fig.6C,D). Moreover,  in L6 myoblasts, 
expression of exogenous PED/PEA-15 reduced PP2A and FoxO1 phosphorylation while PED/PEA-
15 silencing significantly attenuated TGF-beta1 effect on their phosphorylation (Fig.6B,D). At 
variance, transfection of the PEDS116A mutant did not elicit any effect on TGF-beta1-mediated 
autophagy as well as FoxO1 and PP2A dephosphorylation (data not shown). 
 
Importantly, 3-Methyladenine treatment of L6 differentiating cells stably overexpressing 
PED/PEA-15 reduced autophagy to levels similar to those detected in the untransfected cells and 
rescued myotube biochemical and morphological differentiation (Fig.7A-C). Same results were 
obtained in C2C12 (data not shown). Thus, the autophagy-promoting function of PED/PEA-15 
appeared to mediate the induction of autophagy and the impaired myogenesis which follows TGF-
beta1 exposure.  
 
In vivo consequences of skeletal muscle overexpression of PED/PEA-15 - To address the 
significance of these findings to skeletal muscle in vivo, we performed histological analysis of 
tibialis anterior and quadriceps muscles from PED/PEA-15 transgenic mice. These animals have 
been previously described (19,26) and feature about 10-fold overexpression of the PED/PEA-15 
gene in their muscles. As shown in Fig.8A-C, Hematoxylin-Eosin and Engel trichrome stained 
sections revealed a 10% increase in atrophic fibers between PED/PEA-15 transgenic mice and WT. 
(panel A). Rimmed vacuoles (panel B) and vacuoles with red inclusions (panel C) were also 
significantly increased in the PED/PEA-15 transgenic muscles. Staining with specific antibodies 
revealed significantly higher expression of LC3 and Beclin1 in muscles form transgenic compared 
to those of control mice (Fig.8D,E). Indeed, muscles from the PED/PEA-15 transgenic mice 
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revealed a > 4-fold increase in the LC3II to LC3I ratio with similarly-sized reduction in phospho-
PP2A and phospho-FoxO1 levels (Fig.9A). MyoD1 and Myogenin mRNA levels were also 
significantly reduced in muscles from the PED/PEA-15 transgenics (Fig.9B). Whether these 
biochemical changes were paralleled by in vivo functional abnormalities was further analyzed by 
determining transgenic mouse traveled distance in an open field. Interestingly, this test revealed a 
significant decrease in locomotor activity in the PED/PEA-15 transgenic mice (Fig.9C), suggesting 
a causal relationship between the muscle phenotype of these transgenic mice and the control of 
muscle development by PED/PEA-15. 
 
DISCUSSION 
 
Skeletal muscle ontogeny and postnatal physiology are regulated by the TGF-beta family of 
cytokines in different animal systems from mice to humans. Significant advancement has also been 
made in the elucidation of the detailed mechanisms involved in this regulation (1-6). However, 
many aspects of the TGF-beta signalling events leading to its action on skeletal muscle mass remain 
unsettled. In the present work, we have identified the multifunctional protein PED/PEA-15 as a key 
molecule transducing TGF-beta 1 signals and enabling TGF-beta1 repression of the myogenesis 
program.  
 
We now report that, in the L6 and in C2C12  skeletal muscle cells the expression of PED/PEA-15 
gene progressively declines during myogenesis. In addition, exogenous PED/PEA-15 
overexpression inhibits myotubes generation and differentiation leading us to hypothesize that 
PED/PEA-15 is implicated in mechanisms controlling myogenesis. Indeed, we have further found 
that exposure to TGF-beta 1 restrains differentiation and, simultaneously, enhances PED/PEA-15 
gene transcription significantly increasing abundance of PED/PEA-15 protein into the cell. This 
effect appears to be achieved via the TGF-beta1R/SMAD3 pathway activation, as inhibition or 
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silencing of these key molecules significantly impaired PED/PEA-15 upregulation by TGF-beta1. 
Similar effects have been noted also in primary myoblasts from WT and TgPED mice (data not 
shown). Different Smad Response Elements were identified in the PED/PEA-15 promoter region 
whose occupancy increased following L6 cell exposure to TGF-beta1 (data not shown), suggesting 
regulation of PED/PEA-15 gene by TGF-beta1 signalling. Importantly, we show that ShRNAs 
silencing of endogenous PED/PEA-15 and abrogation of PED/PEA-15 phosphorylation at seryl 116 
largely prevented TGF-beta1 action on muscle cell differentiation, indicating that PED/PEA-15 
exerts a major role in mediating the myogenesis control exerted by TGF-beta1. The (TGF-beta1-
mediated)  phosphorylation status of PED/PEA-15  also may play a central role in this process 
because non-phosphorylated PED/PEA-15 lacks the capability to induce myogenic gene expression. 
Despite intensive investigation, how TGF-beta1 inhibits myogenesis has been only partially 
elucidated. Smad3 is the key mediator (27,28), as it physically interacts with both MyoD and 
MEF2C (29). The presence of PED/PEA-15 in this network was unanticipated and led us to explore 
its significance to TGF-beta1 action in greater detail. Autophagy is a dynamic process in which 
intracellular membrane structures, the autophagosomes, sequester proteins and organelles for 
degradation (30). Autophagy is implicated in homeostasis and cell-size regulation in multiple 
organs both during normal development and under stress conditions (31,32). Recently, the role of 
autophagy in muscle differentiation has attracted much attention (11-13). However, it remains 
unclear whether autophagy is detrimental and part of the mechanisms that induce muscle 
degeneration, or whether it is a compensatory mechanism for cell survival. Both TGF-beta1 and 
PED/PEA-15 have been reported to activate autophagy in several tissues, though not in skeletal 
muscle (14,20).  In the present report, we describe that both of these molecules exert an autophagy-
promoting action in the L6 skeletal muscle cells. Importantly, we obtained evidence that PED/PEA-
15 promotion of autophagy mediates the effect of TGF-beta1 on differentiation in the L6 cells. 
Indeed, while silencing of the endogenous PED/PEA-15 blocked TGF-beta1-induced autophagy, 
inhibition with 3-Methyladenine in L6 cells overexpressing PED/PEA-15 reduced autophagy to 
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levels comparable to the untransfected cells and rescued myogenesis. All together, these findings 
led us to conclude that the autophagy-promoting function of PED/PEA-15 mediates both the 
autophagy induction and the impaired myogenesis caused by TGF-beta1. These effects have been 
obtained also in primary myoblasts from WT and TgPED mice (data not shown). 
 
Very recent evidence indicates a direct role of the forkhead transcription factors (FoxOs) in 
regulating the cellular mechanisms responsible for autophagy activation and impairment of 
myoblasts differentiation. Foxo1 ablation in C2C12 cells or in mice increases the levels of MyoD 
while forced expression of FoxO1 upregulates autophagic and atrophic responses in muscle cells 
(12, 22-25, 33). Indeed, FoxOs have been shown to promote the expression of different autophagy-
related genes. These include BECLIN1, ATG8, Gabarapl1, ATG12, ATG4B and VSP34 (21-24). 
FoxO1, in turn, is highly regulated at the post-transcriptional level. Dephosphorylation at Ser256 by 
the Ser/Thr phosphatase PP2A activates FoxO1, inducing its nuclear translocation (34,35). 
Interestingly, PP2A has been shown to undergo activation in response to TGF-beta1 in different cell 
types (36). Here we show that, in the L6 cells, full activation of the PP2A/FoxO1 signalling by 
TGF-beta1 requires PED/PEA-15. Indeed, i. forcing PED/PEA-15 expression is sufficient to 
dephosphorylate PP2A and FoxO1, thus driving the nuclear translocation of FoxO1; and ii., 
PED/PEA-15 silencing significantly attenuates the effect of TGF-beta1 on the PP2A/FoxO1-
transduced signal (34-36). How PED/PEA-15 impacts on PP2A has not been completely 
demonstrated yet. However, data from our own and other laboratories indicate that PED/PEA-15 
induces PKC-delta in different cell types, including the L6 cells. PKC-delta, in turn, enhances PP2A 
activity (37,38), indicating that it might induce PP2A in the L6 cell, as well. 
 
These findings may have in vivo relevance as PP2A and FoxO1 activation accompanied by higher 
levels of autophagy markers and acidic vescicular organelles were also detected in skeletal muscle 
tissue from transgenic mice overexpressing PED/PEA-15. These changes were paralleled by 
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detectable muscle atrophy and decreased locomotor activity in these animals. Indeed, there is now 
evidence that the FoxO family of transcription factors plays a major transcriptional role in the 
muscle atrophy accompanying a number of disorders, including Type 2 diabetes. In the Type 2 
diabetic individual, resistance to insulin in the PI3K/AKT signalling cascade is believed to 
represent a major mechanism responsible for muscle atrophy and sarcopenia, as impaired AKT 
function releases the brake on FoXO1 activity (34,35). However, increased TGF-beta1 levels have 
also been reported in Type 2 diabetes (19). Here we show that TGF-beta1 upregulates PED/PEA-15 
and may contribute to the increased PED/PEA-15 expression described in many individuals with 
type 2 diabetes (17,18). This increased expression has no effect on PI3K/AKT signalling. Thus, 
TGF-beta1 induction of PED/PEA-15, may represent a previously unrecognized mechanism leading 
to FoxO1 activation, impaired myoblasts differentiation, muscle atrophy and decreased muscle 
mass which accompany long-lasting diabetes. This hypothesis is currently under active 
investigation in our laboratory. 
 
In conclusion, in the present report, we have identified PED/PEA-15 as novel molecule in the TGF-
beta1 signaling network of the muscle cell. In this cell types, transcriptional up-regulation of the 
PED/PEA-15 gene by TGF-beta1 induces autophagic responses, atrophy and might contribute to the 
decreased muscle mass accompanying long-lasting Type 2 diabetes. 
 
MATERIAL AND METHODS 
 
Materials. Media, sera, antibiotics for cell culture and the lipofectamine reagent were from 
Invitrogen (Grand Island, NY). The PED/PEA-15 polyclonal antibody and pcDNAII-PED/PEA-15 
vector have been previously described (19). The actin, pSMAD3, SMAD3, PP2A, pPP2A, and 
Beclin1 antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); the FoxO1 and 
pFoxO1 antibodies were from Upstate Biotechnolgy (Lake Placid, NY); LC3 antibodies were from 
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Cell Signaling Technology, Inc (Beverly, MA). TGF-beta1 citokine was from PeproTech, Inc. 
(Rocky Hill, NJ). The phosphorothioate oligonucleotides antisense sequences were as follows: 
SMAD3 AS: 5′-GCAGGATGGACGACAT-3′; SMAD3 S: 5′-GGAGTCAGACTGACGA-3′. 
Protein electrophoresis reagents were purchased from Bio-Rad (Richmond, VA), Western blotting 
and ECL reagents from Amersham Biosciences (Arlington Heights, IL). PED/PEA-15 ShRNA 
vectors and all other chemicals were from Sigma (St. Louis, MO). 
Cell culture procedures and transfection. The L6 muscle and C2C12 cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 10,000 
U/ml penicillin, 10 mg/ml streptomycin, and 2% l-glutamine in a humidified CO2 incubator and 
differentiated as described in (39). Stable transfection of the PED/PEA-15 cDNA and transient 
transfection of antisense oligonucleotides or PED/PEA-15 S116A mutant (PEDS116A) were 
performed by the lipofectamine method according to the manufacturer’s instructions (Invitrogen). 
For these studies, 70 to 80% confluent cells were washed twice with Optimem (Invitrogen) and 
incubated for 8 h with 5 μg of plasmid construct, ShRNA vectors or antisense oligonucleotides 
(200nM) and 45 to 60 μl of lipofectamine reagent. The medium was then replaced with DMEM 
with 10% (vol./vol.) fetal bovine serum and cells further incubated for 15 h before being assayed. In 
transient transfection studies, the medium was then replaced with DMEM with 10% fetal bovine 
serum and cells were further incubated for 15 h before being assayed. For experiments with stably 
transfected cells, individual G418-resistant clones were selected by the limiting dilution technique 
(G418 effective dose, 0.8 mg/ml). The expression of PED/PEA-15 by the individual clones was 
quantitated by Western blotting. In all transfection studies, the efficiency was consistently between 
65 and 75%. Transfection efficiency of antisense oligonucleotides was estimated as 45±10% by co-
transfection with green fluorescent protein. 
TGF-beta1 treatment in differentiating L6 and C2C12 cells. When cells reached ~90% of 
confluence (day 0), the medium was replaced with the differentiation-promoting medium (DMEM 
2% fetal bovine serum), and the cells stimulated with TGF-beta1 (5ng/ml) for 6 or 9 days (cytokine 
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added on days 1, 3, 5 and 1, 3, 5, 7). Control cells were maintained in differentiation medium. The 
cells were then harvested and lysates were analyzed by western blotting, real time PCR, FACS 
analysis on days 6 and 9. 
Mouse generation and phenotyping. The transgenic mice overexpressing PED/PEA-15 have been 
previously described (25). These mice were fertile. Their body weight is comparable to that of their 
wild-type littermates (25). All procedures described below were approved by the Institutional 
Animal Care and Utilisation Committee. Animals were kept in a 12-h dark–light cycle and had free 
access to standard diet. Mice chosen for experimentation were randomly selected from each box of 
mice housed in groups of three to four.  
Open-field exploration. Free exploration in a square arena (walls made of transparent plexiglas 50 
x 50 com, 40 cm high) was allowed as previously described (40). Mice were enabled to explore for 
5 minutes the open-field apparatus, placed in an experimental room with several large-scale 
environmental visual cues and homogeneous illumination. Exploratory behavior was recorded with 
a high definition digital camera and on-line viedeotracking was implemented using custom software 
written in Matlab environment. Total travelled distance was taken as an index of locomotor activity. 
Muscle dissection and immunohistochemical examination. Skeletal muscle specimens (tibialis 
anterior or quadriceps) from PED/PEA-15 transgenic or control mice were processed according to 
(41).  Briefly, dissected muscles were frozen in isopentane pre-cooled in liquid nitrogen and stored 
at -80°C until being further analyzed. Sections (8 µm) were stained with Haematoxylin and Eosin 
(HE), Engel trichrome, or cytochrome C oxidase (COX). 
For immunohistochemical examination, frozen sections (6 µm) were fixed in acetone at 4 °C for 5 
min, then blocked for endogenous peroxidase in 0.3% H2O2 in methanol for 20 min. Muscle 
sections were further incubated with mouse monoclonal antibodies against LC3 (dilution 1:50) and 
BECN1 (dilution 1:50) overnight at 4°C. Slides were washed three times with PBS, incubated with 
biotinylated anti-rabbit and labeled streptavidin biotin (LSAB kit; DakoCytomation, Denmark) for 
30 min, followed by incubation with streptavidin conjugated to horseradish peroxidase (LSAB Kit; 
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DakoCytomation, Denmark). Color development was assessed following 5 minutes of 
diaminobenzidine treatment (DakoCytomation, Denmark) treatment. Sections were counterstained 
with Mayer’s haematoxylin. In the corresponding negative control section, the primary antibody 
was either omitted or replaced with normal mouse serum. 
Tissue and cell lysates and western blot analysis. Tissue samples were homogenised in a Polytron 
(Brinkman Instruments, Westbury, NY, USA) in 20 ml T-PER reagent (Pierce,Rockford, IL, USA) 
per gram of tissue according to the manufacturer’s instructions. After centrifugation at 5000×g for 5 
min, the supernatant fractions were collected. Cells were solubilised in lysis buffer (50 mmol/L 
HEPES, pH 7.5, 150 mmol/L NaCl, 10 mmol/L EDTA, 10 mmol/L Na4P2O7, 2 mmol/L Na3VO4, 
100 mmol/L NaF, 10% (vol./vol.) glycerol, 1% (vol./vol.) Triton X-100, 1 mmol/L PMSF, 10 
mg/ml aprotinin) for 1 h at 4°C and lysates were centrifuged at 5,000×g for 20 min. Total 
homogenates were separated by SDS-PAGE and transferred to 0.45 μm Immobilon-P membranes 
as previously described (20). Upon incubation with primary and secondary antibodies, 
immunoreactive bands were detected by ECL according to the manufacturer's instructions. 
Real-time RT-PCR analysis. Total cellular RNA was isolated from muscles of wild-type and 
PED/PEA-15 transgenic mice using a commercial kit (RNeasy; Qiagen, Hilden, Germany) and 
according to the manufacturer’s instructions. Tissue or cell RNA (1 μg) was reverse-transcribed 
using Superscript III Reverse Transcriptase (Invitrogen). PCR reactions were analysed using SYBR 
Green mix (Invitrogen). Reactions were performed using Platinum SYBR Green qPCR Super-UDG 
and a multicolour real-time PCR detection system (Cycler IQ; Bio-Rad). All reactions were 
performed in triplicate and β-actin was used as an internal standard. Primer sequences were as 
follows: TGF-beta1 (forward) 5′-ATACGCCTGAGTGGCTGTCT-3′, (reverse) 5′-
TGGGACTGATCCCATTGATT-3′; β-actin (forward) 5′-GCGTGACATCAAAGAGAAG-3, 
(reverse) 5′-ACTGTGTTGGCATAGAGG-3′, MyoD1 (forward) 5’-
TCGACTCACCAGACCTGCGCT-3’, (reverse) 5’-CTTGCAGGCCCACAGCAAGC; myogenin: 
(forward) 5’-ACTCCCTTACGTCCATCGTG-3’, (reverse) 5’- CAGGACAGCCCCACTTAAAA-
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3’, Glut4: (forward) 5’- CAGAAGGTGATTGAACAGAG-3’, (reverse) 5'-
AATGATGCCAATGAGAAAGG-3’; Glut1: (forward) 5’- GGGAATGTCCTCATCTTGGA-3’, 
(reverse) 5’- TGAGGCTCTGTGTGGTTCTG-3’. 
Quantification of Acidic Vesicular Organelles with acridine orange. Autophagy in the L6 cells 
was assessed as previously described (42). Briefly, Acidic Vescicular Organellles (AVOs) were 
quantified by acridine orange staining. For these studies cells were treated as necessary for each 
individual experiment and then gently detached with 0.05% trypsin–EDTA followed by 1.0 μ g/mL 
acridine orange staining for 15 minutes at room temperature. Stained cells were then analyzed on a 
FACS cytometer (Dako Cytomation, U.S.A.) and the Summit V4.3 software (Dako) (42). 
Statistical methods. Data were analysed with Statview software (Abacus Concepts, Piscataway, NJ, 
USA) by one-factor analysis of variance. p values of less than 0.05 were considered statistically 
significant (19). 
 
 
ACKNOWLEDGEMENTS 
This work was supported by the European Foundation for the Study of Diabetes (EFSD), the 
European Community’s PREPOBEDIA (201681), grants from the Associazione Italiana per la 
Ricerca sul Cancro (AIRC), and from the Ministero dell’Università e della Ricerca Scientifica 
(MERIT initiative, FIRB program: RBNE08NKH7). The financial contribution of Telethon Italy is 
gratefully acknowledged. 
S.I. and F.O. generated data, discussion, and wrote the manuscript. G.B. researched data, performed 
experimental work, and contributed to discussion. S.C., V.I., D.V. and G.P., researched data, O.P. 
contributed to critical discussion and researched data, P.F. and F.B. directed and planned research 
and wrote the manuscript. 
S.I. and F.O. equally contributed to the study. 
 
16 
REFERENCES 
 
1. Ten Dijke P, Hill CS.  New insights into TGF-beta-Smad signalling. Trends Biochem Sci 
2004; 29: 265–273. 
2.  Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable 
disorders. Cell 2000; 103: 295-309. 
3. Dai C, Liu Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF-β1 in 
mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J Am Soc Nephrol 
2004; 15:1402–1412. 
4. Letterio, JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev 
Immunol 1998; 16:137-61. 
5. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGF-beta 1 and 
fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 2001; 59:463–470.  
6. Toda S, Matsumura S, Fujitani N, Nishimura T, Yonemitsu N, Sugihara H. Transforming 
growth factor-beta1 induces a mesenchyme-like cell shape without epithelial polarization in 
thyrocytes and inhibits thyroid folliculogenesis in collagen gel culture. Endocrinology 1997; 
138: 5561-75.  
7. Massague J, Cheifetz S, Endo T, Nadal-Ginard B. Type beta transforming growth factor is 
an inhibitor of myogenic differentiation. Proc Natl Acad Sci 1986; 83: 8206–8210. 
8. Kollias HD, McDermott JC, Transforming growth factor-beta and myostatin signaling in 
skeletal muscle. J Appl Physiol 2008; 104: 579–587. 
9. Schabort EJ, Van Der Merwe M, Loos B, Moore FP, Niesler CU. TGF-beta's delay skeletal 
muscle progenitor cell differentiation in an isoform-independent manner. Exp Cell Res 
2009; 315: 373-84. 
10. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell 
Biol 2005; 37: 1974–1984 
11. Sandri M. Autophagy in skeletal muscle. FEBS 2010; 584: 1411-6. 
12. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, et al. FoxO3 coordinately 
activates protein degradation by the autophagic/lysosomal and proteasomal pathways in 
atrophying muscle cells. Cell Metab 2007; 6: 472–483. 
13. Masiero E, Agatea L, Mammucari C, Blaauw B, Loro E, Komatsu M, et al. Autophagy is 
required to maintain muscle mass. Cell Metab 2009; 10: 507-15. 
14. Suzuki HI, Kiyono K, Miyazono K. Regulation of autophagy by transforming growth factor-
beta (TGFbeta) signaling. Autophagy  2010; 14: 6. 
17 
15. Araujo H, Danziger N, Cordier J, Glowinski J, Chneiweiss H. Characterization of PEA-15 a 
major substrate for protein kinase C in astrocytes. J Biol Chem 1993; 268: 5911–5920. 
16.  Fiory F, Formisano P, Perruolo G, Beguinot F. Frontiers: PED/PEA-15, a multifunctional 
protein controlling cell survival and glucose metabolism. Am J Physiol Endocrinol Metab 
2009; 297: 592-601. 
17. Condorelli G, Vigliotta G, Iavarone C, Caruso M, Tocchetti CG, Andreozzi F, et al. 
PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes 
mellitus. EMBO J 1998; 7: 3858–3866. 
18. Valentino R, Lupoli G, Raciti GA Oriente F, Farinaro E, Della Valle E, et al. The PEA15 
gene is overexpressed and related to insulin resistance in healthy first degree relatives of 
patients with type 2 diabetes. Diabetologia 2006; 49: 3058–3066. 
19. Oriente F, Iovino S, Cassese A, Romano C, Miele C, Troncone G, et al. Overproduction of 
phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates 
protein kinase C-beta activity and TGF-beta1 expression. Diabetologia 2009; 52: 2642-52. 
20. Böck BC, Tagscherer KE, Fassl A, Krämer A, Oehme I, Zentgraf HW, et al. The PEA-15 
protein regulates autophagy via activation of JNK. J Biol Chem 2010; 285:21644-54. 
21. Pisani DF, Cabane C, Derijard B, Dechesne CA. The topoisomerase 1-interacting protein 
BTBD1 is essential for muscle cell differentiation. Cell Death Differ. 2004; 11: 1157-65.    
22. Salih DA, Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis 
during aging. Curr Opin Cell Biol 2008; 20:126-36. 
23. Sengupta A, Molkentin JD, Yutzey KE. FoxO transcription factors promote autophagy in 
cardiomyocytes. J Biol Chem 2009; 284: 28319-31. 
24. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription 
factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle 
atrophy. Cell 2004; 117: 399-412. 
25. Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, et al. Skeletal muscle 
FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I 
(slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004; 
279: 41114-23. 
26. Vigliotta G, Miele C, Santopietro S, Portella G, Perfetti A, Maitan MA, et al. 
Overexpression of the ped/pea-15 gene causes diabetes by impairing glucose-stimulated 
insulin secretion in addition to insulin action. Mol Cell Biol 2004; 24: 5005-15. 
18 
27. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin 
reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube 
size. Am J Physiol Cell Physiol 2009; 296: 1258-70. 
28. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, et al. Smad2 and 3 
transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009; 
296: 1248-57. 
29. Kollias HD, McDermott JC. Transforming growth factor-b and myostatin signaling in 
skeletal muscle. J Appl Physiol 2007: 104:579-587. 
30. Meléndez A, Neufeld TP. The cell biology of autophagy in metazoans: a developing story. 
Development 2008; 135: 2347-60. 
31.  Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 
2004; 306: 990-5. 
32. Vellai T, Bicsák B, Tóth ML, Takács-Vellai K, Kovács AL. Regulation of cell growth by 
autophagy. Autophagy 2008; 4: 507-509. 
33. Liu CM, Yang Z, Liu CW, Wang R, Tien P, Dale R et al. Effect of RNA oligonucleotide 
targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 
2007; 14: 945-52.    
34. Yan L, Lavin VA, Moser LR, Cui Q, Kanies C, Yang E. PP2A regulates the pro-apoptotic 
activity of FOXO1. J Biol Chem 2008; 283: 7411-20. 
35. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival 
by phosphorylating and inhibiting a Forkhead transcription factor, Cell 1999; 96: 857–868. 
36. Petritsch C, Beug H, Balmain A, Oft M. TGF-beta inhibits p70 S6 kinase via protein 
phosphatase 2A to induce G(1) arrest. Genes Dev 2000; 14: 3093-101. 
37. Renault-Mihara F, Beuvon F, Iturrioz X, Canton B, De Bouard S, Léonard N, et al. 
Phosphoprotein enriched in astrocytes-15 kDa expression inhibits astrocyte migration by a 
protein kinase C delta-dependent mechanism. Mol Biol Cell 2006; 17: 5141-52. 
38. Zhang D, Kanthasamy A, Yang Y, Anantharam V, Kanthasamy A. Protein kinase C delta 
negatively regulates tyrosine hydroxylase activity and dopamine synthesis by enhancing 
protein phosphatase-2A activity in dopaminergic neurons. J Neurosci 2007; 27: 5349-62. 
39. Caruso M, Miele C, Formisano P, Condorelli G, Bifulco G, Oliva A, et al. In skeletal 
muscle, glucose storage and oxidation are differentially impaired by the IR1152 mutant 
receptor. J Biol Chem 1997; 272: 7290-7. 
40. Mignogna P, Viggiano D, Brain distribution of genes related to changes in locomotor 
activity. Physiol Behav 2010; 19: 618-626. 
19 
41. Paciello O, Papparella S. Histochemical and immunohistological approach to comparative 
neuromuscular diseases. Folia Histochem Cytobiol 2009; 47: 143-152. 
42. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric 
cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12. 
 
20 
FIGURE LEGENDS 
 
Fig. 1 – Effect of PED/PEA-15 on L6 cell and C2C12 differentiation. A. L6 and C2C12 cells 
were plated and differentiation was induced as described under Materials and Methods. Upon the 
indicated times in culture, the cells were lysed and protein samples were analysed by Western 
Blotting using PED/PEA-15 antibodies and beta-actin for control. Blots were revealed by ECL and 
autoradiography. Alternatively (left panel),  total RNA was obtained from the cells and PED/PEA-
15 mRNA was assessed by real-time RT-PCR using beta-actin as internal control. Each bar 
represents the mean ± SD of 4 independent experiments, each of which was performed in triplicate. 
B. In L6 and C2C12 cells transfected with a cDNA encoding PED/PEA-15 (pcDNAIII-PED) or the 
empty vector (pcDNAIII), differentiation was induced as described under Materials and Methods. 
C. Differentiated myotubes were then lysed and lysates blotted with PED/PEA-15 antibodies (top 
panel). Alternatively, total RNA was obtained from the cells and MyoD1, Myogenin, GLUT4, Glut1 
and TGF-beta1 mRNAs were quantitated by real-time RT-PCR (bottom panel). Values are 
expressed as % of those in cells transfected with the empty vector. Each bar represents the mean ± 
SD of four independent experiments in triplicate. Asterisks denote statistically significant 
differences (*p < 0.05; **p < 0.01). Brightfield images of the L6 and C2C12 cells (100 x 
magnification) transfected with either the PED/PEA-15 cDNA or with the empty vector upon 6 
days in culture. The microphotographs shown are representative of five other independent sets of 
observations. 
 
Fig.2 – Effect of TGF-beta 1 on PED/PEA-15 expression in L6 and C2C12 cells. A. Skeletal 
muscle cells were stimulated with 5 ng/mL TGF-beta1 for the indicated times. Total RNA was then 
isolated from the cells and the levels of PED/PEA-15 mRNA were assessed by real-time RT-PCR 
using beta-actin as internal control. Alternatively, the cells were treated with 0.1 µM of the TGF-
beta1 receptor inhibitor SB431542 or transiently transfected with 200 nM SMAD3 
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phosphorothioate antisense (SMAD3 AS) followed by stimulation with 5 ng/ml TGF-beta1, as 
described under Materials and Methods. The cells were then harvested for assessment of PED/PEA-
15 mRNA levels (B) or Western blotted with specific PED/PEA-15, phospho-SMAD3 (pSMAD3) 
and SMAD3 antibodies (C). Blots were revealed by ECL and autoradiography using beta-actin as a 
loading control. The autoradiograps shown are representative of four independent experiments. Bars 
represent the mean ± SD of four independent experiments. Asterisks denote statistically significant 
differences (* p < 0.05; **p < 0.01, ***p < 0.001). 
 
Fig.3 – The role of PED/PEA-15 in TGF-beta1-impaired myogenesis in L6 cells. L6 myoblasts 
were transfected either with a scrambled or a PED/PEA-15 ShRNAs and maintained in culture 
enabling them to differentiate for the indicated times and in the presence or the absence of 5 ng/mL 
TGF-beta1. Total RNA preparations were then obtained from the cells and the levels of MyoD1 (A), 
Myogenin (B), Glut4 (C) and PED/PEA-15 mRNA (D) were quantitated by real-time RT-PCR 
analysis, using beta-actin as internal standard. Each bar represents the mean ± SD of four 
independent experiments in which each reaction was performed in triplicate. Asterisks denote 
statistically significant differences (# p<0.01 for differences between Sc at day 6 or 9 and Sc at day 
0, *p < 0.05; **p < 0.01, ***p < 0.001). 
 
Fig.4 – The role of PED/PEA-15 phosphorylation in TGF-beta1-impaired myogenesis in L6 
cells. L6 cells transfected with the empty (pcDNAIII) or the PED/PEA-15 (pcDNAIII-PED) vector  
or the PED/PEA-15 S116A mutant (PEDS116A) were maintained in culture enabling them to 
differentiate for the indicated times and in the presence or the absence of 5 ng/mL TGF-beta1. Total 
RNA preparations were then obtained from the cells and the levels of MyoD1 (A), Myogenin (B), 
Glut4 (C) and PED/PEA-15 mRNA (D) were quantitated by real-time RT-PCR analysis, using beta-
actin as internal standard. Each bar represents the mean ± SD of four independent experiments in 
which each reaction was performed in triplicate. Asterisks denote statistically significant 
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differences (# p<0.01 for differences between Sc at day 6 and Sc at day 0, **p < 0.01, ***p < 
0.001). 
 
Fig.5 – TGF-beta1 effect on autophagy in L6 and C2C12 cells. A. Differentiating L6 cells were 
treated with 5 ng/mL TGF-beta1 as described under Materials and Methods. After 6 days in culture, 
the cells were stained with acridine orange and AVO accumulation was determined by flow 
cytometric analysis. Calculated percentages represent the red-positive cells in the upper quadrants 
(R10 and R11). FITC Lin, green color intensity; PE Texas Red Area, red color intensity. Those 
shown are representative of four independent experiments. Alternatively (B,D), L6 and C2C12 cells 
were lysed as described under Materials and Methods and Western blotted using PED/PEA-15, 
Beclin1, LC3 I, LC3 II, phospho-Tyr307-PP2A, phospho-Ser256-FoxO1 or FoxO1 antibodies. 
Blots were revealed by ECL and autoradiographs, using beta-actin as loading control. The 
autoradiographs shown are representative of three independent experiments. C. L6 and C2C12 cells 
were plated and exposed for 72h to 5 ng/mL TGF-beta1 in the absence or the presence of 1 mM 3-
Methyladenine (3MA). Upon 6 days of differentiation, total RNA was isolated and the levels of 
MyoD1, Myogenin and Glut4 mRNA were quantitated by real-time RT-PCR analysis, with each 
reaction performed in triplicate. Bars represent the mean ± SD of four independent experiments. 
 
Fig.6 – PED/PEA-15 autophagy promoting activity mediates TGF-beta1 action on L6 cell 
differentiation. L6 cells stably overexpressing PED/PEA-15 (pcDNAIII-PED) or transfected with 
the empty vector (pcDNAIII) were plated and enabled to differentiate as described under Materials 
and Methods. AVO accumulation was determined as outlined in Fig.4 (A). The one shown is 
representative of 4 independent experiments. B. Alternatively, the cells were lysed and 100 
microgram protein samples were analyzed by Western blotting using the indicated antibodies. Blots 
were revealed by ECL and autoradiography, using beta-actin as loading control. The autoradiograph 
shown is representative of three independent experiments. C. Differentiated myotubes were 
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transiently transfected with either the ShPED/PEA-15 RNA (Sh PED/PEA-15) or a scrambled RNA 
(Sc) and then exposed to 5 ng/mL TGF-beta1. AVO accumulation was assessed as outlined in 
Fig.4. The one shown is representative of three independent experiments. D. Alternatively, the cells 
were lysed and protein samples were analyzed by Western blotting using the indicated antibodies. 
Blots were revealed by ECL and autoradiography, using beta-actin as loading control. The 
autoradiograph shown is representative of four independent experiments. 
 
Fig.7 – 3-Methyladenine rescues differentiation in PED/PEA-15 overexpressing L6 cells. L6 
myoblasts stably overexpressing PED/PEA-15 were plated and differentiated in culture as described 
under Materials and Methods. 72 hour prior to the experiment, the cells were exposed to 1 mM 3-
Methyladenine (3MA). AVO accumulation was then assessed as outlined under Fig.4 (A). The 
figures shown are representative of four independent experiments. Alternatively, total RNA was 
obtained by the cells followed by quantitation of MyoD1, Myogenin, GLUT4 and GLUT1 mRNA 
levels by RT-PCR, using beta-actin as internal standard (B). Data are presented as % of the levels 
measured in control cells. Bars represent the mean ± SD of four independent experiments in which 
each reaction was performed in triplicate. Asterisks denote statistically significant differences (**p 
< 0.01, ***p < 0.001). C. Brightfield images (100 x) of L6 cells stably transfected with either the 
PcDNAIII-PED vector or the empty PcDNAIII vector in the absence or the presence of 3-
Methyadenine. The microphotographs shown are representative of three additional experiments. 
 
Fig.8 – Histological and immunohistochemical analysis of skeletal muscles from PED/PEA-15 
transgenic mice. Sections from skeletal muscles (tibialis anterior) from 6- month old transgenic 
mice and non transgenic littermates (control; WT) were stained with either Hematoxylin-Eosin 
(H/E; A,B) or Engel-Trichrome (C) or immunostained with LC3 or Beclin1 (BECN1) antibodies 
(D,E). The arrows in the microphotographs (40 x) indicate atrophic muscle fibers with basophilic 
cytoplasm (A), small rimmed vacuoles (B), vacuoles with red inclusions (C), decoration with LC3 
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(D) and Beclin1 (BECN1; E) antibodies. The microphotographs shown are representative of 
findings observations in 6 transgenic and 8 non-transgenic animals. 
 
Fig.9 – Functional consequences of PED/PEA-15 overexpression in skeletal muscle of 
transgenic mice. A.Tibialis anterior muscles from PED/PEA-15 transgenic mice and from their 
non transgenic littermates (WT) were dissected, solubilized and 100 microgram protein samples 
were analyzed by Western blottin using LC3-I, LC3-II, phospho-tyr307-PP2A (P-PP2A), PP2A, 
phospho-ser256-FoxO1 (p-FoxO1) and FoxO1 antibodies. Beta actin was used as loading control. 
Blots were revealed by ECL and autoradiography. The autoradiograph shown is representative of 
studies performed with n=8 mice/group. Alternatively (B), the muscle were used for obtaining total 
RNA preparation. MyoD1 and Myogenin mRNA was subsequently assessed by realtime RT-PCR 
analysis, using beta-actin as internal standard. Bars represent the mean ± SD of four independent 
experiments each performed in triplicate C. Travel distance was compared in transgenic and non 
transgenic littermates (16 animals/group) enabled to explore the open-field appartus for 5 min. as 
described under Materials and Methods. Bars represent the mean ± SD of four independent studies 
each involving 4 mice/group. Asterisks denote statistically significant differences (*p < 0.05; ***p 
< 0.001). 
 
Supplemental Figure 1 – PED/PEA-15 mediates TGF-beta1 action on L6 cell differentiation. 
L6 cells were transfected either with a PED/PEA-15 ShRNA or a scramble RNA, exposed to 5 
ng/mL TGF-beta1 and cultured for the indicated times. The microphotographs shown are brightfield 
images (100 x magnification) representative of four independent sets of observations. 
 
 
 
025
50
75
100
125
P
E
D
/P
E
A
1
5
 m
R
N
A
  
(%
 o
f 
c
o
n
tr
o
l)
 
A 
** 
** 
* 
PED 
ACTIN 
B 
PcDNAIII PcDNAIII-PED 
Fig. 1 
0 1 3 6 9 Days 
Myotubes Myoblasts 
0 2 
** 
L6 C2C12 
0 1 3 6 9 
Myotubes Myoblasts 
L6 
Days 0 2 
C2C12 
PED 
ACTIN 
0
100
200
300
400
m
R
N
A
 l
e
v
e
ls
  
(%
 o
f 
c
o
n
tr
o
l)
 
* ** 
Myogenin 
Glut4 
MyoD1 
Glut1 C 
** * * * 
L6 C2C12 
L6 C2C12 
L6 C2C12 
PcDNAIII PcDNAIII-PED 
Fig. 2 
-       +        -        + 
-       -         +       + 
TGF-beta1  
SB 431542   
p-SMAD 3 
ACTIN 
-       +        -        + 
-       -         +       + 
0
200
400
600
P
E
D
/P
E
A
1
5
 m
R
N
A
  
 
(%
 o
f 
c
o
n
tr
o
l)
 
   -  +        -  +       -  +       -  + 
   -  -        +  +       -  -        -  -   
TGF-beta1  
SB 431542  
** 
* 
* 
** 
B 
C 
SMAD 3 
** * 
* 
** 
     -  -         -  -        -  -       + + SMAD 3 AS  
PED 
SMAD3 AS  -       -         -        - -       -         +       + 
Sc       -  -         -  -        + +       -  - 
Sc -       -         -        - +      +         -        - 
0
200
400
600
 TGF-beta1  
incubation  
time (hours) 
P
E
D
/P
E
A
1
5
 m
R
N
A
  
 
(%
 o
f 
c
o
n
tr
o
l)
 ** 
** * 
A 
 0  2 6  0  2 6 
L6 C2C12 
** 
* 
Fig. 3 
M
y
o
g
e
n
in
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
B A 
G
lu
t4
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
C D 
0
100
200
300
Day 9 Day 6 Day 0 
P
E
D
/P
E
A
1
5
  
m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
0
200
400
600
800
M
y
o
D
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
# 
0
100
200
300
Day 9 Day 6 Day 0 
0
100
200
300
Day 9 Day 6 Day 0 
# 
** 
** 
** ** * 
** ** 
# 
# 
** * 
** ** 
** 
** 
** 
# 
* 
# 
** 
* 
ShPED1 
TGF-beta1 + Sc 
Sc ShPED2 
TGF-beta1 + ShPED1 
TGF-beta1 + ShPED2 
* 
** 
* 
** 
* 
*** 
** 
* 
Fig. 4 
B A 
G
lu
t4
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
C 
D 
P
E
D
/P
E
A
1
5
  
m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
0
200
400
600
800
TGF-beta1 + PcDNAIII-PED 
PcDNAIII-PED 
TGF-beta1 
PcDNAIII 
PEDS116A 
TGF-beta1 + PEDS116A 
M
y
o
D
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
M
y
o
g
e
n
in
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
0
50
100
150
200
250
# 
** 
** 
** * 
Day 6 Day 0 
# 
** 
** 
** * 
Day 6 Day 0 
0
50
100
150
200
250
0
50
100
150
200
250
# 
** 
** 
** * 
Day 6 Day 0 
** 
** 
TGF-beta1  A 
FITC Lin 
0 64 128 256 192 
0 
64 
128 
256 
192 
R12 R13 
R10 R11 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
1.8% 
Ctrl 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
FITC Lin 
0 64 128 256 192 
0 
64 
128 
256 
192 
R12 R13 
R10 R11 
27% 
BECN1 
LC3 I 
LC3 II 
PED/PEA15 
ACTIN 
B 
Fig. 5 
C 
0
25
50
75
100
125
M
y
o
D
1
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
M
y
o
g
e
n
in
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
G
lu
t4
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
** 
** 
*** 
D 
PP2A 
p-PP2A 
p-FoxO1 
FoxO1 
ACTIN 
L6 C2C12 
L6 C2C12 
* 
0
25
50
75
100
125
** 
0
25
50
75
100
125
** 
L6 C2C12 
Fig. 6 
pcDNAIII-PED 
12% 
LC3 I 
LC3 II 
BECN1 
ACTIN 
PED 
A 
TGF-beta1  
BECN1 
LC3 I 
LC3 II 
ACTIN 
C 
p-FoxO1 
FoxO1 
p-PP2A 
PP2A 
B 
0  
PED/PEA15 
p-PP2A 
PP2A 
FoxO1 
D 
p-FoxO1 
pcDNAIII 
0,87% 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
Sh PED1  
0,5% 
9% 25% 
Sc  
1,1% 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
FITC Lin 
FITC Lin 
FITC Lin FITC Lin 
FITC Lin FITC Lin 
PcDNAIII-PED 
PcDNAIII-PED + 3MA 
PcDNAIII 
Fig. 7 
C 
A 
B 
PcDNAIII PcDNAIII-PED 
PcDNAIII-PED + 
3MA 
PcDNAIII PcDNAIII-PED PcDNAIII-PED + 3MA 
0
100
200
300
m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
** ** 
** 
*** 
myoD1 myogenin Glut4 Glut1 
1,5% 12% 4% 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
P
E
-T
e
x
a
s
 R
e
d
 A
re
a
 
FITC Lin FITC Lin FITC Lin 
Fig. 8 
A 
H/E 
H/E 
B 
Engel 
trichrome 
C 
BECN1 
E 
LC3 
D 
Transgenic mice for 
PED/PEA15 (TgPED)  
Control mice (WT) 
Fig. 9 
0
50
100
M
y
o
D
1
 m
R
N
A
 
(%
 o
f 
c
o
n
tr
o
l)
 
0
50
100
M
y
o
g
e
n
in
 m
R
N
A
  
(%
 o
f 
c
o
n
tr
o
l)
 
p-FoxO1 
FoxO1 
p-PP2A 
PP2A 
A 
TgPED WT 
TgPED WT 
B 
LC3 I 
LC3 II 
ACTIN 
Wt TgPED 
0
500
1000
1500
2000
T
ra
v
e
l 
d
is
ta
n
c
e
 
(c
m
) 
Wt TgPED 
*** C 
*** 
* 
Day 6 
Day 6 TGF-beta1 +Sc 
Day 9 
Day 6 TGF-beta1 + ShPED 
Day 9 TGF-beta1 + Sc 
Day 9 TGF-beta1 + ShPED 
Supplemental Fig. 1 
